Celecoxib (SC 58635)

Name: Celecoxib (SC 58635)
Brand: Selleck Chemicals
SKU: S1261
Rating: 5 (71 reviews)

For research use only.

Licensed by Pfizer Catalog No.S1261

71 publications

CAS No. 169590-42-5

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Selleck's Celecoxib (SC 58635) has been cited by 71 publications

J Immunother Cancer, 2021, 9(6)e002305

PubMed: 34168004 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(3)1194

PubMed: 33530480 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )

J Clin Invest, 2020, 26;132417

PubMed: 32452837 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6299

PubMed: 33288764 ( click the link to review the publication )

Nat Commun, 2020, 11(1):6339

PubMed: 33311482 ( click the link to review the publication )

Cell Death Differ, 2020, 20

PubMed: 32433558 ( click the link to review the publication )

Nanotoxicology, 2020, 14(2):162-180

PubMed: 31703536 ( click the link to review the publication )

Cells, 2020, 14;9(5):E1222

PubMed: 32423044 ( click the link to review the publication )

Aging (Albany NY), 2020, 12

PubMed: 33180744 ( click the link to review the publication )

Neoplasia, 2020, 22(11):576-589

PubMed: 32980776 ( click the link to review the publication )

J Inflamm Res, 2020, 13:1043-1055

PubMed: 33293848 ( click the link to review the publication )

J Clin Periodontol, 2020, 10.1111/jcpe.13283

PubMed: 32160330 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Brain Res, 2020, 20;1740:146846

PubMed: 32325074 ( click the link to review the publication )

AAPS PharmSciTech, 2020, 17;21(5):135

PubMed: 32419073 ( click the link to review the publication )

Biol Open, 2020, 9(11)bio053447

PubMed: 33148606 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Cell Death Dis, 2020, 11(8):626

PubMed: 32796811 ( click the link to review the publication )

Cell Death Dis, 2020, 11(3):172

PubMed: 32139667 ( click the link to review the publication )

Osteoarthritis Cartilage, 2020, 28(4):502-515

PubMed: 32061965 ( click the link to review the publication )

Int Immunopharmacol, 2020, 81:106206

PubMed: 32018066 ( click the link to review the publication )

EBioMedicine, 2019, 47:142-155

PubMed: 31492557 ( click the link to review the publication )
Cancer Lett, 2019, 440-441:116-125

PubMed: 30343113 ( click the link to review the publication )

Cell Death Dis, 2019, 10(6):397

PubMed: 31113934 ( click the link to review the publication )

Front Pharmacol, 2019, 10:836

PubMed: 31440159 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2019, 145(6):1495-1507

PubMed: 31028540 ( click the link to review the publication )

Int J Biochem Cell Biol, 2019, 116:105610

PubMed: 31518663 ( click the link to review the publication )

Front Pediatr, 2019, 7:228

PubMed: 31231624 ( click the link to review the publication )

Endocr J, 2019, 10.1507/endocrj.EJ19-0015

PubMed: 31105125 ( click the link to review the publication )

Viruses, 2019, 11(12)

PubMed: 31842327 ( click the link to review the publication )

Chin J Dent Res, 2019, 22(4):221-227

PubMed: 31859282 ( click the link to review the publication )

Nat Biomed Eng, 2018, 2(8):578-588

PubMed: 31015631 ( click the link to review the publication )

Sci Transl Med, 2018, 10(433)

PubMed: 29563317 ( click the link to review the publication )

Theranostics, 2018,

PubMed: 30083255 ( click the link to review the publication )

Chem Res Toxicol, 2018, 31(2):127-136

PubMed: 29156121 ( click the link to review the publication )

Oncol Lett, 2018, 16(4):4526-4536

PubMed: 30214587 ( click the link to review the publication )

Oncol Lett, 2018, 16(1):317-325

PubMed: 29928417 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9425-9441

PubMed: 29507700 ( click the link to review the publication )

Mucosal Immunol, 2018, 11(6):1663-1673

PubMed: 30082707 ( click the link to review the publication )

Nat Cell Biol, 2017, 19(10):1274-1285

PubMed: 28892080 ( click the link to review the publication )

Cancer Res, 2017, 77(3):790-801

PubMed: 27940576 ( click the link to review the publication )

Theranostics, 2017, 7(5):1389-1406

PubMed: 28435473 ( click the link to review the publication )

J Transl Med, 2017, 15(1):46

PubMed: 28231855 ( click the link to review the publication )

Biomed Pharmacother, 2017, 89:1235-1241

PubMed: 28320090 ( click the link to review the publication )

Oncol Rep, 2017, 38(5):2657-2666

PubMed: 29048666 ( click the link to review the publication )

J Pharm Biomed Anal, 2017, 145:586-592

PubMed: 28783595 ( click the link to review the publication )
Biochem Biophys Res Commun, 2017, 490(2):567-573

PubMed: 28624453 ( click the link to review the publication )

Biomed Res Int, 2017, 2017:2948467

PubMed: 29250535 ( click the link to review the publication )

Oncol Lett, 2017, 14(5):5959-5965

PubMed: 29113232 ( click the link to review the publication )

Biochim Biophys Acta Gen Subj, 2017, 1861(2):264-275

PubMed: 27894925 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 29245915 ( click the link to review the publication )

Oncotarget, 2017,

PubMed: 28978083 ( click the link to review the publication )

Oncotarget, 2017, 8(31):51748-51757

PubMed: 28881683 ( click the link to review the publication )

Oncotarget, 2017, 8(46):80651-80665

PubMed: 29113333 ( click the link to review the publication )

Cell Rep, 2016, 16(12):3334-3347

PubMed: 27653694 ( click the link to review the publication )

J Pharm Sci, 2016, 105(3):1113-23

PubMed: 26886329 ( click the link to review the publication )

Oncol Lett, 2016, 12(5):3836-3844

PubMed: 27895738 ( click the link to review the publication )

Oncotarget, 2016, 7(19):28435-47

PubMed: 27078846 ( click the link to review the publication )

Oncotarget, 2016, 7(35):57077-57085

PubMed: 27494851 ( click the link to review the publication )

J Biol Chem, 2015, 290(52):30988-1002

PubMed: 26518876 ( click the link to review the publication )

J Cell Physiol, 2015, 230(5):1115-27

PubMed: ( click the link to review the publication )

Int J Pharm, 2015, 496(2):382-91

PubMed: 26468038 ( click the link to review the publication )

Int J Biochem Cell Biol, 2015, 69:132-41

PubMed: 26510582 ( click the link to review the publication )

Drug Des Devel Ther, 2015, 9:5851-62

PubMed: 26586936 ( click the link to review the publication )

Biochem Bioph Res Co, 2015, 10.1016/j.bbrc.2015.03.008

PubMed: 25770423 ( click the link to review the publication )

Anticancer Res, 2015, 35(5):2699-708

PubMed: 25964548 ( click the link to review the publication )

Br J Pharmacol, 2014, 171(2):498-508

PubMed: 24372551 ( click the link to review the publication )

J Cell Physiol, 2014, 10.1002/jcp.24919

PubMed: 25546329 ( click the link to review the publication )

Blood, 2011, 118(22):5891-900

PubMed: 21865341 ( click the link to review the publication )

Purity & Quality Control

Choose Selective COX Inhibitors

Biological Activity

Description

Celecoxib (SC 58635) is a selective COX-2 inhibitor with IC50 of 40 nM in Sf9 cells.

Targets

COX-2 ^[1]
(Sf9 cells)

40 nM

In vitro

Celecoxib shows low sensitivity against COX-1 with IC50 of 15 μM. ^[1] Celecoxib shows an anti-proliferative effect on nasopharyngeal carcinoma (NPC) cell lines including HNE1 and CNE1-LMP1 with IC50 of 32.86 μM and 61.31 μM, respectively. ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
A549	NYTLc2NGTnWwY4Tpc44hSXO\|YYm=	M2OyOlAvOS1\|MDFOwG0>	NH72[Yk1QCCq		MnLSbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw>	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjVzM{G3Nkc,OjZ3MUOxO\|I9N2F-
H460	MULGeY5kfGmxbjDBd5NigQ>?	MWewMlEuOzBizszN	M2jLPFQ5KGh?		MlrpbY5lfWOnczDJR2FONTFiZYjwdoV{e2mxbjDvckBjd3SqIIDyc5RmcW5iYX7kJI1TVkFibHX2[Yw>	NELXTnk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkWxN\|E4Oid-Mk[1NVMyPzJ:L3G+
HKESC-2	NWLHTXZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NX\OZlFxOjEEoN88US=>	MorxOFjDqGkEoB?=		MUXzbYdvcW[rY3HueIx6KGmwY4LlZZNmeyC2aHWgTWM2OMLidnHseYV{KG:oIH;4ZYxqeGyjdHnuxsA>	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR5NE[5N{c,OjZ2N{S2PVM9N2F-
CaES-17	NHLmWWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXXSWmZjOjEEoN88US=>	NFn3SlM1QMLiaNMg		NIfie3B{cWewaX\pZ4FvfGy7IHnuZ5Jm[XOnczD0bIUhUUN3MNMgeoFtfWW\|IH;mJI95[WyrcHzheIlvyqB?	NIW5[4k9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS3OFY6Oyd-Mk[0O\|Q3QTN:L3G+
HKESC-2	M{nsV2Fxd3C2b4Ppd{BCe3OjeR?=	M{nvUlIxyqEQvF2=	MkLHOFjDqGkEoB?=		NXSx[mdUemWmdXPld{BwgGGuaYDsZZRqdi2rbnT1Z4VlKGGyb4D0c5Nqew>?	MofWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2N{S2PVMoRjJ4NEe0Olk{RC:jPh?=
CaES-17	NEL3PZBCeG:ydH;zbZMhSXO\|YYm=	NGDPN\|MzOMLizszN	MUS0POKhcMLi		MV;y[YR2[2W\|IH;4ZYxqeGyjdHnuMYlv\HWlZXSgZZBweHSxc3nz	NXTs[JpGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[0O\|Q3QTNpPkK2OFc1Pjl\|PD;hQi=>
A549	M{X5Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7	M{mzZ\|UuOTZyIN88US=>	MXO0POKhcMLi	NFHhNmtFVVOR	MWrJR\|UxRTF4Mz60JO69VQ>?	NGLoe4s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkS2OFY1Oyd-Mk[0OlQ3PDN:L3G+
HCC827	NUjrSmwyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NEPBVXQ2NTF4MDFOwG0>	M2LPXVQ5yqCqwrC=	NVXXe\|VmTE2VTx?=	NXLkWJZHUUN3ME22PU4zKM7:TR?=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR4NE[0N{c,OjZ2NkS2OFM9N2F-
A549	M4LxXmFxd3C2b4Ppd{BCe3OjeR?=	M4TB[FgxKML3TR?=	NH;1bmE1QMLiaNMg	MnLsSG1UVw>?	NEnZepVqdmS3Y3XzJIFxd3C2b4Ppdy=>	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR4NE[0N{c,OjZ2NkS2OFM9N2F-
HCC827	MX;BdI9xfG:\|aYOgRZN{[Xl?	Mkm3PFAhyrWP	MmfWOFjDqGkEoB?=	NX3zU3dQTE2VTx?=	MkDnbY5lfWOnczDhdI9xfG:\|aYO=	MmrUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2NkS2OFMoRjJ4NE[0OlQ{RC:jPh?=
SGC-7901/DDP	NWrDSFA5TnWwY4Tpc44hSXO\|YYm=	MUCxNOKhyrWP	M{TDe\|I1KGh?		NXvLXJB1cW6qaXLpeJMh[3mlbH;vfJlo\W6jc3WtNkBidmRiUD3ncJlkd3C{b4TlbY4h\XiycnXzd4lwdg>?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{[1N{c,OjZ2MEe2OVM9N2F-
SGC-7901	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NULsUFlbOjUEoHlCpC=>		MnPtTWM2OD1zMUWuNFgh\|ryP	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{[1N{c,OjZ2MEe2OVM9N2F-
SGC-7901/DDP	M2DDVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NFnrfJozPMLiaNMg		MlLNTWM2OD1\|NT60OUDPxE1?	Ml3iQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ2MEe2OVMoRjJ4NEC3OlU{RC:jPh?=
SGC-7901/DDP	NIS1Om5CeG:ydH;zbZMhSXO\|YYm=	MoSyNVDDqML3TR?=	M2m3UlI1KGh?		M2XM[Ilv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhid3n0bEBkcXOybHH0bY4>	MVG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{[1N{c,OjZ2MEe2OVM9N2F-
SGC-7901/DDP	MnzNSpVv[3Srb36gRZN{[Xl?	MmniNVDDqML3TR?=	M1;YTVI1KGh?		MlTPbY5pcWKrdIOgeIhmKGW6cILld5Nqd25ib3[gVE1odHmlb4Dyc5RmcW5idHjyc5VocCCkbH;jb4lv\yCHUEKsJIFv\CCrbnHjeIl3[XSrbnegVGtCKGGwZDDDVmVDyqB?	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjRyN{[1N{c,OjZ2MEe2OVM9N2F-
SGC-7901/DDP	Mlv1SpVv[3Srb36gRZN{[Xl?	MoPUNVDDqML3TR?=	NHjQXXozPCCq		NETuVVBk[XW\|ZYOgZUBu[XKtZXSg[IVkemWjc3WgbY4hfGinIHzleoVtKG:oIFLjcE0zKHC{b4TlbY4>	M1\YZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ4NEC3OlU{Lz5{NkSwO\|Y2OzxxYU6=
H357	NHnrNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NFLiR4Q4NjVxMUCg{txO	NV\teG9{PDhiaB?=	NFPBdlhFVVOR	NXHxNndDcW6qaXLpeJMh[2WubDDndo94fGkEoHPvcYJqdmWmIIfpeIghW2GkdYTvZ4xigA>?	NWDhOlAyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[wNFk5PzRpPkK2NFA6QDd2PD;hQi=>
TAF	M3\jemZ2dmO2aX;uJGF{e2G7	M33ESlExyqEEtV2=	M{O1Wlch\A>?		M1TrPIFn\mWldIOgWGFHeyCjZHjld4l3\SCycn;w[ZJ1cWW\|	MluxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7OEexNlcoRjJ3OUi3NVI4RC:jPh?=
TAF	M1;yR2Z2dmO2aX;uJGF{e2G7	NYjrcWsxOTEEoNM1US=>	M2rOcVMxNTF{MDDtbY4>		MVTwc49zdHliYX\m[YN1eyCmQXv0JJBpd3OyaH;yfYxifGmxbjDjc45{\XG3ZX70JJRwKEWJRjDzbYdv[Wyrbne=	M1S0TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUi3NVI4Lz5{NUm4O\|EzPzxxYU6=
TAF	NWG3TZFrTnWwY4Tpc44hSXO\|YYm=	NWjxXVV1OTEEoNM1US=>	M1P5W\|Q5KGh?		MlPVbY5kemWjc3XzJGVITlJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w	MWG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl6N{GyO{c,OjV7OEexNlc9N2F-
PANC-1	MmDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NGPSW4gzOC94MD:xNFAh\|ryP	MX[yOE81QC95MjDo		M2C4folvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MlvLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV7N{OwOlIoRjJ3OUezNFYzRC:jPh?=
PANC-1	M4DxdGZ2dmO2aX;uJGF{e2G7	MonONlAwPjBxMUCwJO69VQ>?	NWPydJl7OjRiaB?=		MUHheJRmdnWjdIOgZ4VtdCCrbo\hd4lwdiCjbnSgcYloemG2aX;uJIlvKGFiY3;uZ4VvfHKjdHnvck1l\XCnbnTlcpQhdWGwbnXyxsA>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTl5M{C2Nkc,OjV7N{OwOlI9N2F-
HeLa	M1Ww[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYqyNOKh\|ryPwrC=	MVSyOOKhcA>?		M2Tz[YVvcGGwY3XzJJJi\GmjdHnvck1qdmS3Y3XkJIlvcGmkaYTpc44hd2ZiY3XscEBxem:uaX\ldoF1cW:w	NVz3b\|JGRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3O\|A1OjNpPkK1O\|cxPDJ\|PD;hQi=>
SACC-83	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NF\JZo0zOMLizszNxsA>	MoDuNlTDqGh?		NXfPdZJx\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36=	Mkj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5N{C0NlMoRjJ3N{ewOFI{RC:jPh?=
HeLa	Mk\qRZBweHSxc3nzJGF{e2G7	NYjGcppTOjEEoN88UeKh	MnLtNlTDqGh?		NX:1fVh7\W6qYX7j[ZMhemGmaXH0bY9vNWmwZIXj[YQhcW6qaXLpeIlwdiCxZjDj[YxtKGGyb4D0c5Nqew>?	NIL2O3g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3NFQzOyd-MkW3O\|A1OjN:L3G+
SACC-83	NFvMcopCeG:ydH;zbZMhSXO\|YYm=	M{Xwe\|IxyqEQvF5CpC=>	NVnlTFYxOjUEoHi=		Mln3[Y5p[W6lZYOgdoFlcWG2aX;uMYlv\HWlZXSgbY5pcWKrdHnvckBw\iClZXzsJIFxd3C2b4Ppdy=>	M1j4N\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{ewOFI{Lz5{NUe3NFQzOzxxYU6=
HeLa	NVfCe25uTnWwY4Tpc44hSXO\|YYm=	MV2yNE81OC96MDFOwG0>	NWr5VWk3OjUEoHi=		NXyxfXBnfXC{ZXf1cIF1eyCSVFXOJJBienSrYXzsfUBjgSCrbnjpZol1cW6pIGPwNUwh[W6mIHHjeIl3[XSnczDQWGVPKGGwZDDpcoFkfGm4YYTld{BCU1R?	NF;GcpI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUe3NFQzOyd-MkW3O\|A1OjN:L3G+
SACC-83	M4rtc2Z2dmO2aX;uJGF{e2G7	MWGyNE81OC96MDFOwG0>	Ml;ENlTDqGh?		NGS5XIN2eHKnZ4XsZZR{KFCWRV6gdIFzfGmjbHz5JIJ6KGmwaHnibZRqdmdiU4CxMEBidmRiYXP0bZZifGW\|IGDUSW4h[W6mIHnuZYN1cX[jdHXzJGFMXA>?	M17USFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{ewOFI{Lz5{NUe3NFQzOzxxYU6=
HLCZ01	Ml3NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NX;ES\|hFOOLCk{[wxsDDvU1?	NG[3XVY1QCCq	NFTs[JNFVVOR	MUnpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NIfTNmQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUeyOFg6QSd-MkW3NlQ5QTl:L3G+
HLCZ01	NGn1TldHfW6ldHnvckBCe3OjeR?=	M2LaW\|QxyqEQvF2=	M1LLWlI1KGh?	M3rFSmROW09?	NWCwS2ZQcW6lcnXhd4V{KGGlY4XteYxifGmxbjDv[kBIOC:JMT3wbIF{\SClZXzsd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	NWT2d45qRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW3NlQ5QTlpPkK1O\|I1QDl7PD;hQi=>
HLCZ01	NWG5c5ZNSXCxcITvd4l{KEG\|c3H5	MlnmOFDDqM7:TR?=	MlS0NlQhcA>?	NFLFemdFVVOR	M3:4PYVvcGGwY3XzJIFxd3C2b4Ppd{Bkd22kaX7l[EB4cXSqIFnGUk3PuQ>?	MnjOQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkS4PVkoRjJ3N{K0PFk6RC:jPh?=
HLCZ01	NF:xXFJHfW6ldHnvckBCe3OjeR?=	MUm0NOKh\|ryP	NIXVfHozPCCq	MnjpSG1UVw>?	MojYbY5kemWjc3XzJHRTSUmOIHX4dJJme3Orb36gZ49u[mmwZXSge4l1cCCLboTldoZmem:wLd8x	Mkf3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV5MkS4PVkoRjJ3N{K0PFk6RC:jPh?=
MGC803	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVLORWZDOC14MDFOwG0>	NUfYV4dbPzJiaB?=		M12ydWlEPTB;NEeuNlXjiIoEsfMAjVYvPDNizszN	M{P2O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CxN\|c5Lz5{NUewNVM4QDxxYU6=
SGC7901	NUDTXYs6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MkezNE03OCEQvF2=	NGPwbWM4OiCq		NF6yPZBKSzVyPUSzMlU{6oDLwsJihKk2NjF{IN88US=>	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTdyMUO3PEc,OjV5MEGzO\|g9N2F-
MGC803	NYmwdIJsTnWwY4Tpc44hSXO\|YYm=	NVrBfpNOPDEEoN88US=>	MYq4M\|E3NzJ2IHi=		NFroZoJ2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44>	M{TGOFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CxN\|c5Lz5{NUewNVM4QDxxYU6=
SGC7901	MnvySpVv[3Srb36gRZN{[Xl?	NHfpbYQ1OMLizszN	NVfiNYxWQC9zNj:yOEBp		NHr2b3h2eHKnZ4XsZZR{KEOkbD3iJIV5eHKnc4Ppc44>	M4e4UFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3N{CxN\|c5Lz5{NUewNVM4QDxxYU6=
MCF-7	NH30Tm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MXixM\|ExKM7:TR?=	M1[xfVczKGh?	NEfVeXZFVVOR	M13VdIVvcGGwY3XzJINidGOrdILpc4wucW6mdXPl[EBk\WyuIHfyc5d1cCCrbnjpZol1cW:w	M{nFN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[3OVExLz5{NU[2O\|UyODxxYU6=
MDA-MB-231	NGHPZopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4r1clEwOTBizszN	MUe3NkBp	NF30TmFFVVOR	NUK1R5pG\W6qYX7j[ZMh[2GuY3n0dolwdC2rbnT1Z4VlKGOnbHyg[5Jwf3SqIHnubIljcXSrb36=	M1nNSFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3Nk[3OVExLz5{NU[2O\|UyODxxYU6=
MDA-MB-231	NG[2VIhHfW6ldHnvckBCe3OjeR?=	MUSwMVQxKML3TR?=	MYq0MVI1KGh?		NXewT3FJcW6lcnXhd4V{KEORWD2yJJBzd3SnaX6g[ZhxemW\|c3nvckBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	MmrnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV3OEezNlkoRjJ3NUi3N\|I6RC:jPh?=
MCF-7	NXnHV\|J6TnWwY4Tpc44hSXO\|YYm=	MYewMVQxKML3TR?=	M2CxelQuOjRiaB?=		MXvlcohidmOnczD0bIUh\W[oZXP0d{Bw\iCWUFGgc44hSUKFR{Kg[ZhxemW\|c3nvcuKh	M2HrblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NUi3N\|I6Lz5{NUW4O\|MzQTxxYU6=
MCF7-MX	NIX2dJhHfW6ldHnvckBCe3OjeR?=	MkfjNE01OCEEtV2=	MXK0MVI1KGh?		MnfV[Y5p[W6lZYOgeIhmKGWoZnXjeJMhd2ZiVGDBJI9vKEGEQ1eyJIV5eHKnc4Ppc47DqA>?	NF7j[Vg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUW4O\|MzQSd-MkW1PFc{Ojl:L3G+
MDA-MB-231	NFXs[Y1HfW6ldHnvckBCe3OjeR?=	NYfOSnJsOC12MDFCuW0>	MV:0MVI1KGh?		MVjzeIlufWyjdHXzJJRp\SCneIDy[ZN{cW:wIH;mJGFDS0d{IIXwJJRwKDRwMkegeIlu\XNidH:gZ49vfHKxbDDs[ZZmdCCkeTCxNkBpyqB?	MXe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPTV6N{OyPUc,OjV3OEezNlk9N2F-
A2780	M3XzUmZ2dmO2aX;uJGF{e2G7	MkXEOU8yOC9zNTFOwG0>	Mo\BOFghcA>?		MlT4[IVkemWjc3XzJGNwgC1{IHX4dJJme3Orb36gbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M4DoPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK0PFk5Lz5{NUSyOFg6QDxxYU6=
SKOV3	NWLiV2xKTnWwY4Tpc44hSXO\|YYm=	M4XV[\|UwOTBxMUWg{txO	M4r4T\|Q5KGh?		NVzVe3ZG\GWlcnXhd4V{KEOxeD2yJIV5eHKnc4Ppc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	Mlj3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkS4PVgoRjJ3NEK0PFk5RC:jPh?=
A2780	MmDGSpVv[3Srb36gRZN{[Xl?	NWj3d4xLPS9zMD:xOUDPxE1?	NIm1b5M1QCCq		NEW5bWJmdGW4YYTld{B1cGViZYjwdoV{e2mxbjDv[kBGNWOjZHjldolvKGGwZDDr[ZJifGmw	NWjtOZlWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlQ5QThpPkK1OFI1QDl6PD;hQi=>
SKOV3	NF3MO2NHfW6ldHnvckBCe3OjeR?=	MkHHOU8yOC9zNTFOwG0>	NVPQT5JTPDhiaB?=		NYT1U3Ax\WyndnH0[ZMhfGinIHX4dJJme3Orb36gc4YhTS2lYXTo[ZJqdiCjbnSgb4Vz[XSrbh?=	NGPtWGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOFg6QCd-MkW0NlQ5QTh:L3G+
A2780	NEf4cJFHfW6ldHnvckBCe3OjeR?=	Mmn2OU8yOC9zNTFOwG0>	MV20PEBp		MWnk[YNz\WG\|ZYOgeIhmKGW6cILld5Nqd25ib3[gUk1k[WSqZYLpckBidmRiVnnt[Y51cW5?	NF;kTVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUSyOFg6QCd-MkW0NlQ5QTh:L3G+
SKOV3	NVHvbYhGTnWwY4Tpc44hSXO\|YYm=	M{[5VlUwOTBxMUWg{txO	MWi0PEBp		Mmjw[IVkemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJG4u[2GmaHXybY4h[W6mIG\pcYVvfGmw	NXfjZ2I5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0NlQ5QThpPkK1OFI1QDl6PD;hQi=>
A2780	MkXjSpVv[3Srb36gRZN{[Xl?	NFTrZlk2NzFyL{G1JO69VQ>?	MUGxJIg>		Mn3PbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M{i0[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NEK0PFk5Lz5{NUSyOFg6QDxxYU6=
SKOV3	NXTPcIhpTnWwY4Tpc44hSXO\|YYm=	M3LkbVUwOTBxMUWg{txO	MV[xJIg>		MknZbY5kemWjc3XzJJRp\SCneIDy[ZN{cW:wIH;mJJAuSUuWIHHu[EBxNUWUSzDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	MkLxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2MkS4PVgoRjJ3NEK0PFk5RC:jPh?=
HCT-15	MXfGeY5kfGmxbjDBd5NigQ>?	NH\XSXEyOC13MDFOwG0>	NHjUT2U3NTN4IHi=		NYfuU4twcW6mdXPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDpckBjd3SqIHTvd4Uh[W6mIITpcYUh\GWyZX7k[Y51KG2jbn7ldi=>	M2L2V\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG4NFI5Lz5{NUKxPFAzQDxxYU6=
HT-29	MWjGeY5kfGmxbjDBd5NigQ>?	NGfMU2YyOC13MDFOwG0>	M1[3[FYuOzZiaB?=		NEeydmxqdmS3Y3XzJJRp\SCneIDy[ZN{cW:wIH;mJGNQYC1{IHnuJIJwfGhiZH;z[UBidmRidHnt[UBl\XCnbnTlcpQhdWGwbnXy	M1\yU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkG4NFI5Lz5{NUKxPFAzQDxxYU6=
HSC3	M{fnUWNmdGxiVnnhZoltcXS7IFHzd4F6	MXOw5qCUPDBizszN	MVK0PEBp		M{\rc2lEPTB;MkWuOeKyOS55OECg{txO	NHv2Nms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUG5PFc5QSd-MkWxPVg4QDl:L3G+
HSC3	NYDxZ\|l5SXCxcITvd4l{KEG\|c3H5	MUiyOUDPxE1?	NFm3ZnU1QCCq		M2roTolv\HWlZYOgZZBweHSxc3nz	MmGwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUi3PFkoRjJ3MUm4O\|g6RC:jPh?=
HSC3	MUPGeY5kfGmxbjDBd5NigQ>?	MYCyOUDPxE1?	NFzr[lE1QCCq		M1nCTYV5cGmkaYTzJJNq\26rZnnjZY51dHlicnXkeYNm\CCvaXfyZZRqd25iY3;tZolv\WRid3n0bEBETVR?	MlzEQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUi3PFkoRjJ3MUm4O\|g6RC:jPh?=
HSC3	MWHGeY5kfGmxbjDBd5NigQ>?	M{XUPFI2KM7:TR?=	NF30UnI1QCCq		MYjpcohq[mm2czDIV2M{KGOnbHygbY53[XOrb36gZ49u[mmwZXSge4l1cCCFRWS=	MmXsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzOUi3PFkoRjJ3MUm4O\|g6RC:jPh?=
HSC3	NWfsc5NRTnWwY4Tpc44hSXO\|YYm=	M4n5flI2KM7:TR?=	Mnz6O\|IhcA>?		Ml\Q[IVkemWjc3XzJG1OWC1{IHHu[EBOVVBvOTDwdo91\Wmwc9Mg	NXfzNYZ4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxPVg4QDlpPkK1NVk5Pzh7PD;hQi=>
201T	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		M2q5b\|czKGh?	M2eycGROW09?	M2jSdGlEPTB;NEiuOkDDvU1?	NUe3dnVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVc6PDFpPkK1NFU4QTRzPD;hQi=>
273T	Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1zY[\|czKGh?	NGSxVnNFVVOR	NVzYeYw6UUN3ME24NE42KML3TR?=	NULHbotrRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOVc6PDFpPkK1NFU4QTRzPD;hQi=>
Hep-2	MnfaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MUWzNE82OC9zMECg{txO	MoPiNVIwOjRxM{[vOFghcA>?	NHrwXnlFVVOR	NYLuV2sxcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lJIFv\CCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	Ml\pQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUi1OlQoRjJ2OUm4OVY1RC:jPh?=
Hep-2	NWPRZ5RjSXCxcITvd4l{KEG\|c3H5	MnflOVAh\|ryP	MXqwMVQ5KGh?	NIS1cHlFVVOR	Mn;zbY5lfWOnczDhdI9xfG:\|aYOgbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK=	NV7JU\|NFRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5PVg2PjRpPkK0PVk5PTZ2PD;hQi=>
Hep-2	NFL5PGxHfW6ldHnvckBCe3OjeR?=	M1TwdFUxKM7:TR?=	NGLWSXMxNTR6IHi=	MV3EUXNQ	NFPBPHRz\WS3Y3XzJJRp\SC2ZXzvcYVz[XOnIHHjeIl3cXS7IHfyZYR2[WyueR?=	M1HKblxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUm4OVY1Lz5{NEm5PFU3PDxxYU6=
Hep-2	MkKwSpVv[3Srb36gRZN{[Xl?	NXK4UJlpPTBizszN	NUKwTI44OC12ODDo	NV\IV5NETE2VTx?=	MnHH[IVkemWjc3XzJJRp\SCvUl7BJIV5eHKnc4Ppc44hd2ZiaGTFVnQ>	NGrKUY09[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5PFU3PCd-MkS5PVg2PjR:L3G+
SGC-7901	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NUDLeIxlOTBxNUCvNVAxKM7:TR?=	MV2yOE81QC95MjDo	MmizSG1UVw>?	MUDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWViYX7kJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NFfafoQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
MKN-45	M4TUSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NEDSOGgyOC93MD:xNFAh\|ryP	MYqyOE81QC95MjDo	NVewTFV{TE2VTx?=	M1\TfYlvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZTDhcoQh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	MnWxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7OUK5OVgoRjJ2OUmyPVU5RC:jPh?=
SGC-7901	MVfGeY5kfGmxbjDBd5NigQ>?	M1fQdVExNzVyL{GwNEDPxE1?	MlrvOFghcA>?	MnLaSG1UVw>?	MX;kc5dvemWpdXzheIV{KHSqZTDtVm5CKGW6cILld5Nqd25ibHX2[Yx{KG:oIFPPXE0zKGGwZDDQR25CKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVz	MYi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDl7Mkm1PEc,OjR7OUK5OVg9N2F-
MKN-45	M{\xdWZ2dmO2aX;uJGF{e2G7	NYr2WHplOTBxNUCvNVAxKM7:TR?=	NFHabmM1QCCq	NGixc2FFVVOR	NH7RPZZld3ewcnXneYxifGW\|IITo[UBuWk6DIHX4dJJme3Orb36gcIV3\Wy\|IH;mJGNQYC1{IHHu[EBRS06DIHnuJIEh\G:\|ZTDk[ZBmdmSnboSgcYFvdmW{	NGey[oI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm5Nlk2QCd-MkS5PVI6PTh:L3G+
C666-1	NInBTJBEgXSxdH;4bYNqfHliQYPzZZk>	MW[yNE05OCEQvF2=	NETz[lczPCCq		NWr6dVR2\GWlcnXhd4V{KGOxbH;ufUBnd3KvYYTpc44hcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZLDqA>?	M{O2cVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OEW0PFM5Lz5{NEi1OFg{QDxxYU6=
CNE-1	M{PMTmN6fG:2b4jpZ4l1gSCDc4PhfS=>	NGW2[mYzOC16MDFOwG0>	MkPRNlQhcA>?		MW\k[YNz\WG\|ZYOgZ49td267IH\vdo1ifGmxbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nctMg	NGfPb\|U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEi1OFg{QCd-MkS4OVQ5Ozh:L3G+
CNE-2	MnLVR5l1d3SxeHnjbZR6KEG\|c3H5	M2\ySFIxNThyIN88US=>	NUjqV3VPOjRiaB?=		NGTubpBl\WO{ZXHz[ZMh[2:ub375JIZwem2jdHnvckBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7lduKh	Mn7MQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
C666-1	M2nxN2N6fG:2b4jpZ4l1gSCDc4PhfS=>	Ml\5OlAh\|ryP	NX7r[VkyPyCm		NIrzUYhmdmijbnPld{Bz[WSrYYTpc44h[3m2b4TvfIlkcXS7IITodo92\2hiQ1;YMVIu\GWyZX7k[Y51KG2jbn7ldi=>	MlzkQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR6NUS4N\|goRjJ2OEW0PFM5RC:jPh?=
CNE-1	MkPjR5l1d3SxeHnjbZR6KEG\|c3H5	NHzOSJc3OCEQvF2=	MWC3JIQ>		NWfGTmxC\W6qYX7j[ZMhemGmaXH0bY9vKGO7dH;0c5hq[2m2eTD0bJJwfWeqIFPPXE0zNWSncHXu[IVvfCCvYX7u[ZI>	MWW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDh3NEizPEc,OjR6NUS4N\|g9N2F-
SNU-1041	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MWiwMVQxKM7:TR?=	MUK0PEBp		MX;pcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NI\USHM9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[5NlcxOyd-MkS2PVI4ODN:L3G+
SNU-1041	NHvUTYJHfW6ldHnvckBCe3OjeR?=	MXKyNE8{OCEQvF2=	NWruZYhFPCCq		NFzpd4RqdmS3Y3XzJIV5eHKnc4Ppc44hd2cEoFPIU3AtKEeUUEe4xsBidmUEoGjCVFHDqGG2IITo[UBTVkFibHX2[YzDqA>?	NU\lbVBsRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2PVI4ODNpPkK0OlkzPzB\|PD;hQi=>
SNU-1041	NXLkPHVmTnWwY4Tpc44hSXO\|YYm=	NFOwOogxNTRyIN88US=>	MnjXOEBp		NIjhWJp2eC2{ZXf1cIF1\XNiQ1jPVOKh[W[2ZYKgeJJm[XSvZX70JJdqfGhiaHnnbEBkd26lZX70doF1cW:wcx?=	NHjjcXU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[5NlcxOyd-MkS2PVI4ODN:L3G+
SGC-7901	Ml[4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHnjVII2OC1zMkWg{txO	M3m4PVI1NzR6L{eyJIg>		NF71bGRqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWgZY5lKGSxc3Wg[IVx\W6mZX70JI1idm6nch?=	Mo\YQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{[zPVQoRjJ2Nke2N\|k1RC:jPh?=
SGC-7901	MVLBdI9xfG:\|aYOgRZN{[Xl?	NWfFTI52OTByIN88US=>	NWTENJBFPzJiaB?=		MVnpcoR2[2W\|IHHwc5B1d3Orcx?=	NETvRYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3OlM6PCd-MkS2O\|Y{QTR:L3G+
SGC-7901	MkTDSpVv[3Srb36gRZN{[Xl?	NH[2dlE4PS9zMECvNVI2KM7:TR?=	NEnQOnMzPC92OD:3NkBp		NGqxV2dqdmO{ZXHz[ZMh[2G\|cHHz[U05KGGwZDCtPUBuWk6DIHX4dJJme3Orb36gbY4h[m:2aDD0bY1mKGGwZDDkc5NmKG2jbn7ldi=>	Mn3oQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{[zPVQoRjJ2Nke2N\|k1RC:jPh?=
LMeC	M3e2bWZ2dmO2aX;uJGF{e2G7	NHXXUGQzOC93MDFOwG0>	M3jCfVQ5KGh?		M1;SUIRm[3KnYYPld{B1cGViZYjwdoV{e2mxbjDv[kBEV1hvMjDwdo91\Wmw	MWO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
CMeC-1	NHnFOoVE\WyuIG\pZYJqdGm2eTDBd5NigQ>?	NF;4Z3ozOC93MDFOwG0>	NETWeYw1QCCq		Ml3JbY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ?	NG[0O409[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1Olc1Pid-MkS2OVY4PDZ:L3G+
LMeC	NXHFfVlHS2WubDDWbYFjcWyrdImgRZN{[Xl?	NGPxNpYzOC93MDFOwG0>	NEi2VnI1QCCq		MXrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meg>?	NGC0To89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[1Olc1Pid-MkS2OVY4PDZ:L3G+
CMeC-1	MlfESpVv[3Srb36gRZN{[Xl?	MXGyNE82OCEQvF2=	NXfBUWFTPDhiaB?=		MVTpcoR2[2W\|IFexMXMh[XK{ZYP0	M4mwT\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
LMeC	NEDzbmZHfW6ldHnvckBCe3OjeR?=	MmXSNlAwPTBizszN	M4rqN\|Q5KGh?		M1jCV4lv\HWlZYOgS\|EuWyCjcoLld5Q>	MkHMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[3OFYoRjJ2NkW2O\|Q3RC:jPh?=
CMeC-1	MlXxSpVv[3Srb36gRZN{[Xl?	MUGyNE82OCEQvF2=	NWPoZWtlPDhiaB?=		NFWwNndl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDjfYNtcW5iREGgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	M3LJdlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkW2O\|Q3Lz5{NE[1Olc1PjxxYU6=
LMeC	M4HqemZ2dmO2aX;uJGF{e2G7	M{f3UlIxNzVyIN88US=>	NFvDT4k1QCCq		MnzJ[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZiY4njcIlvKERzIHnuJIEh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	MmLLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[3OFYoRjJ2NkW2O\|Q3RC:jPh?=
CMeC-1	NGLQfG1HfW6ldHnvckBCe3OjeR?=	NISzfpMzOC93MDFOwG0>	MnT4OFghcA>?		NX\zcGJGcW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
LMeC	NUC2cINyTnWwY4Tpc44hSXO\|YYm=	NXXPSm9pOjBxNUCg{txO	M2ntcFQ5KGh?		NYPrdmxncW6mdXPld{Bk[XOyYYPlMVMh[WO2aY\heIlwdg>?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ3Nke0Okc,OjR4NU[3OFY9N2F-
OVCAR-3	MULD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	MWKxNEDDvU1?	MlrwNUBp		M364OoVvcGGwY3XzJJBi[2yrdHH4[YwucW6mdXPl[EBwfmG{aXHuJINidmOncjDj[YxtKGSnYYToxsA>	M4HlOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NUKwNlI4Lz5{NEWyNFIzPzxxYU6=
OVCAR-3	MVTBdI9xfG:\|aYOgRZN{[Xl?	NXLufJhlOTBiwsXN	NV\qfpI5OSCq		NHfYdmVxem:vb4Tld{Bx[WOuaYThfIVtNWmwZIXj[YQh[XCxcITvd4l{yqB?	NGDnSo49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEWyNFIzPyd-MkS1NlAzOjd:L3G+
OVCAR-3	M1zFfmZ2dmO2aX;uJGF{e2G7	NYGxeWh1OTBiwsXN	NILvOpQyKGh?		NEH2[2JmdmijbnPld{Bx[WOuaYThfIVtNWmwZIXj[YQh[WO2aY\heIlwdiCxZjDjZZNx[XOnLUpCpC=>	NWToPWlURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NlAzOjdpPkK0OVIxOjJ5PD;hQi=>
OVCAR-3	MnjOSpVv[3Srb36gRZN{[Xl?	Mm\DNVAhyrWP	Mly3NUBp		MnLH[I94di2{ZXf1cIF1\XNiTl[t{tpDKGGldHn2ZZRqd25iaX7keYNm\CCkeTDwZYNtcXSjeHXs	MmPIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MkCyNlcoRjJ2NUKwNlI4RC:jPh?=
OVCAR-3	NEfjPXRHfW6ldHnvckBCe3OjeR?=	MmnTNVAhyrWP	M{PIeFEhcA>?		NYe0cIlNcW6qaXLpeJMheGGlbHn0ZZhmdC2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25?	MmHUQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MkCyNlcoRjJ2NUKwNlI4RC:jPh?=
CF33	NYPHNYwyTnWwY4Tpc44hSXO\|YYm=	NGHpVlMyODBizszN	M4f3WFI1KGh?		NXfkeZJFcW6mdXPld{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMjDwdo91\WmwIHX4dJJme3Orb36=	MonuQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEO3PFIoRjJ2NUCzO\|gzRC:jPh?=
CF33	MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2LmNVExNTFyMDFOwG0>	NHfZXmsxNTRiZB?=		NV3hPIlkcW6qaXLpeJMh[2WubDDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NWnSR5pURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS1NFM4QDJpPkK0OVA{Pzh{PD;hQi=>
CF33	Ml7HSpVv[3Srb36gRZN{[Xl?	M3XvXFExNTFyMDFOwG0>	MkexOE0zPCCq		Mof6[IVkemWjc3XzJINmdGy\|IHnuJJRp\SCVIIDoZZNmKGGwZDDpcoNz\WG\|ZYOgZ4VtdHNiaX6gS\|AwTzFiYYLy[ZN1	MlTDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR3MEO3PFIoRjJ2NUCzO\|gzRC:jPh?=
LNCaP	NVnu[JlNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M3LoT\|IwPS9zMDFOwG0>	NW\6ZZZKQTZiaB?=		NHnWWlZqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|aXfubYZq[2GwdHz5JINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu	NGG1eGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEK5Olk4QCd-MkSyPVY6Pzh:L3G+
LNCaP	M2DP[WFxd3C2b4Ppd{BCe3OjeR?=	NEXpTIszNzVxMUCg{txO	NEH1VHI6PiCq		M2HCcIlv\HWlZYOgZZBweHSxc3nzJINwdWKrbnXkJJdqfGhiYYTvdpZie3SjdHnu	M3HMeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm2PVc5Lz5{NEK5Olk4QDxxYU6=
PC-3	NH7mXJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NXLOTlA2OC13MDFOwG0>	MVi0PQKBkWh?		MYDpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=>	NXPDV4pqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSxNlc5QDJpPkK0NVI4QDh{PD;hQi=>
PC-3	M3S1bWNmdGxiVnnhZoltcXS7IFHzd4F6	M2T1T\|AuOTByIN88US=>	MnTiO\|IhcA>?		NGC2dWJl\WO{ZXHz[ZMh[2WubDD2bYFjcWyrdImgbY4h[SCmb4PlJIRmeGWwZHXueEBu[W6wZYK=	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDF{N{i4Nkc,OjRzMke4PFI9N2F-
HCA-7	M{j1N2Z2dmO2aX;uJIF{e2G7		NX7kXW9YPzJiaILz		NX\KbWY{UW6qaXLpeIlwdiCxZjDJUE0y[mW2YT3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdiCrbjDoeY1idiCKQ1GtO{Bk\WyuczDh[pRmeiB5MjDodpMh[nliRVnBMEBGSzVyIE2gNE4xODFzNTFOwG0v	NFLXSYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkWxOlI5Oid-MkK1NVYzQDJ:L3G+
CHO	MYLGeY5kfGmxbjDhd5NigQ>?				M3P1XmlvKH[rdILvJIlvcGmkaYTvdpkheG:2ZX7jfUBi\2GrboP0JIh2dWGwIFPPXE0zKGmwIIP0ZYJtgSC2cnHud4Zm[3SnZDDjbIlv\XOnIHjhcZN1\XJib4\hdpkhMEOKTzmgZ4VtdHNuIFnDOVAhRSByLkCwNkDPxE1w	Mk\jQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTB3N{[2PFQoRjFyNUe2Olg1RC:jPh?=
CHO	NVXIe\|M{TnWwY4Tpc44h[XO\|YYm=				M4DUXmlvcGmkaYTpc44hd2ZiUFfFMVIheHKxZIXjeIlwdiCrbjDDTG8h[2WubIOg[ZhxemW\|c3nu[{BpfW2jbjDDU3guOixiSVO1NEA:KDBwMECyJO69VS5?	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yODV5Nk[4OUc,OTB3N{[2PFU9N2F-
CHO	MVXGeY5kfGmxbjDhd5NigQ>?				MoP3TY4hfmm2cn:gdI91\W6leTDh[4FqdnO2IHj1cYFvKFC{b4P0ZYdt[W6maX6gS{9JKHO7boToZZNmKDJiaX6geJJidnOoZXP0[YQhS0iRIHPlcIx{NCCLQ{WwJF0hOC5yMEKg{txONg>?	M13OW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzFyMUm3PVcxLz5zMEG5O\|k4ODxxYU6=
CHO	NXnuVnhyTnWwY4Tpc44h[XO\|YYm=				M1z6NWlvcGmkaYTvdpkhd2ZiaIXtZY4hWHKxc4Th[4xidmSrbjDHM2ghe3mwdHjhd4UhOiCneIDy[ZN{\WRiaX6gR2hQKGOnbHzzMEBKSzVyIE2gNE4xODJizszNMi=>	M4nPSVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF{NkSzPVQzLz5zMk[0N\|k1OjxxYU6=
synovial cells	MXnGeY5kfGmxbjDhd5NigQ>?				MUfJcohq[mm2b4L5JIVn\mWldDDvckBxem:mdXP0bY9vKG:oIHP5Z4xwd3i7Z3XuZZNmNTJiKFPPXE0zMSCycn;zeIFodGGwZHnuJGUzKCiSR1WyLUBqdiCqdX3hckBKVDFvYnX0ZUB{fGmvdXzheIVlKHO7bn;2bYFtKGOnbHzzMEBKSzVyIE2gNE4xODd7IN88UU4>	NIPmOGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMEiyNVcyPid-MUC4NlE4OTZ:L3G+
RAW264.7	MV3GeY5kfGmxbjDhd5NigQ>?				NHqzOlVKdmirYnn0bY9vKG:oIFPPXE0zKGmwIH3veZNmKFKDV{K2OE44KGOnbHzzJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIFzQV{1qdmS3Y3XkJHBITTJicILv[JVkfGmxbjD0doVifGWmIIDybY9zKHSxIFzQV{BkcGGubHXu[4Uh[nliZX76fY1mKGmvbYXuc4F{e2G7LDDJR\|UxKD1iMD6wNFg4KM7:TT6=	MoXPQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4NU[2OlIoRjJ2NkW2OlYzRC:jPh?=
HEK293	MXLGeY5kfGmxbjDhd5NigQ>?				MlzITY5pcWKrdHnvckBw\iClbH;u[YQhW3S7bH;wbI9z[SCyaYP0bYxt[XSjIHHsdIhiNUODIHX4dJJme3OnZDDpckBpfW2jbjDISWszQTNiY3XscJMh[nlic4TvdJBm\C2obH;3JGNQOiCjc4PhfUwhU2liPTCwMlA{PDJizszNMi=>	M{LwbFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUKwOVc4Lz5zOUWyNFU4PzxxYU6=
SF9	M3LWRWZ2dmO2aX;uJIF{e2G7				NWKwfGNIUW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KGi3bXHuJHBzd3O2YXfsZY5lcW5iRz;IJJN6dnSqYYPlJFIh\XiycnXzd4VlKGmwIIPmMVkh[2WubIOgbY5n\WO2ZXSge4l1cCCkYXP1cI93cXK3czygTWM2OCB;IECuNFM3KM7:TT6=	M{Cy[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF2Nkm4NVkxLz5zNE[5PFE6ODxxYU6=
SF9	NUjkOWRYTnWwY4Tpc44h[XO\|YYm=				M3;VUGlvKH[rdILvJIlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDy[YNwdWKrbnHueEBxem:\|dHHncIFv\GmwIFevTEB{gW62aHHz[UAzKGW6cILld5Nm\CCrbjDz[k06KGOnbHzzJIlv\mWldHXkJJdqfGhiYnHjeYxwfmm{dYOsJGlEPTBiPTCwMlA{PiEQvF2u	NXG4[mVlRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUWwNlYxPTBpPkG1NFI3ODVyPD;hQi=>
CHO	NUe1SGhETnWwY4Tpc44h[XO\|YYm=				MlPQTY5pcWKrdHnvckBw\iCFT2iyJIV5eHKnc4Pl[EBqdiCFSF:gZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCjcnHjbIlld26rYzDhZ4llNXO2aX31cIF1\WRiUFfFNkBxem:mdXP0bY9vKGK7IHXufplu\SCrbX31co9ie3OjeTygTWM2OCB;IECuNFM3KM7:TT6=	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTV4NkK5NEc,OTV3Nk[yPVA9N2F-
insect cells	MX;GeY5kfGmxbjDhd5NigQ>?		NYjCbZhmOSCvaX6=		NYnMUGt3UW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDDU3gzKGW6cILld5Nm\CCrbjDpcpNm[3RiY3XscJMhfXOrbnegZZJi[2irZH;ubYMh[WOrZDDhd{B{fWK\|dILheIUhcW6ldXLheIVlKG[xcjCxJI1qdiCycnnvdkB1dyC\|dXLzeJJifGViYXTkbZRqd25ibXXhd5Vz\WRiZn;yJFI2KHOnY4OgZpkhXE2SRD3iZZNm\CClaILvcY9o\W6rYzDhd5NigSxiSVO1NEA:KDBwMESyJO69VS5?	M13vPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|MEGwNlcxLz5{M{CxNFI4ODxxYU6=
HNSCC 1483	NIrZSoFHfW6ldHnvckBie3OjeR?=		Mo[2N\|AhdWmwcx?=		M1\Qc2lvcGmkaYTpc44hd2ZiQ1;YMVIhcW5iaIXtZY4hUE6VQ1OgNVQ5OyClZXzsd{B2e2mwZzDbNVREZSCjcnHjbIlld26rYzDhZ4llKGG\|IIP1ZpN1emG2ZTDwdoVqdmO3YnH0[YQh\m:{IEOwJI1qdnNiYnXmc5JmKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zMEBKSzVyIE2gNE4xPTRizszNMi=>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjJ4M{i5OEc,OjJ{NkO4PVQ9N2F-
J774	NYDhWVM2TnWwY4Tpc44h[XO\|YYm=				MlP2TY5pcWKrdHnvckBw\iCFT2iyJIlvKEySUz3zeIlufWyjdHXkJGo4PzRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRT0V{IHzleoVteyCkeTDyZYRqd2mvbYXuc4F{e2G7LDDJR\|UxKD1iMD6wOkDPxE1w	M4e5ZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUG1PFU1Lz5zN{mxOVg2PDxxYU6=
J774	NWfXRWhITnWwY4Tpc44h[XO\|YYm=		Mo\0NVUhdWmwcx?=		NF7TZmVKdmirYnn0bY9vKG:oIFPPXFIhcW5iTGDTMZN1cW23bHH0[YQhdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJHBITTJicILv[JVkfGmxbjDh[pRmeiBzNTDtbY5{KGK7IILh[IlwcW2vdX7vZZN{[XluIFnDOVAhRSByLkC2JO69VS5?	NYfLU\|drRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVI6PTdpPkG4O\|UzQTV5PD;hQi=>
J774	MnPVSpVv[3Srb36gZZN{[Xl?		MWWyOEBpenN?		NUG1WpRGUW6qaXLpeIlwdiCxZjDDU3guOi2vZXTpZZRm\CCSR1WyJJBzd2S3Y4Tpc44hcW5iTGDTMZN1cW23bHH0[YQhdW:3c3WgTlc4PCClZXzsd{Bi\nSncjCyOEBpenNiYomgdoFlcW:rbX31co9ie3OjeTygTWM2OCB;IECuNFYyKM7:TT6=	NHT2RlQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm5NlE4Pid-MkG5PVIyPzZ:L3G+
J774	NYTMVlVMTnWwY4Tpc44h[XO\|YYm=				MoPMTY5pcWKrdHnvckBw\iCFT2iyJIlvKG2xdYPlJGo4PzRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNvaX7keYNm\CCSR1WyJJBzd2S3Y4Tpc44h[nlicnHkbY9qdW23bn;hd5NigSxiSVO1NEA:KDBwME[xJO69VS5?	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MES0OEc,OjN4OEC0OFQ9N2F-
SF9	NIT1cXNHfW6ldHnvckBie3OjeR?=				MXvJcohq[mm2aX;uJI9nKGi3bXHuJGNQYDJiZYjwdoV{e2WmIHnuJIJi[3Wub4\pdpV{NWmwZnXjeIVlKFOIOTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKGG{YXPobYRwdmmlIHHjbYQue3SrbYXsZZRm\CCSR1WyJJBzd2S3Y4Tpc44hfHKnYYTl[EAyKGi{IHLl[o9z\SCjcnHjbIlld26rYzDhZ4llKGOqYXzs[Y5o\SCkeTDlcpp6dWViaX3teY5w[XO\|YYmsJGlEPTBiPTCwMlA3OyEQvF2u	NHLJd\|M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUWyNFU4Oyd-MUm1NlA2PzN:L3G+
COS	NHrGcmFHfW6ldHnvckBie3OjeR?=				NXXJRZI1UW6qaXLpeIlwdiCxZjDoeY1idiCleXPsc495gWenbnHz[U0zKGW6cILld5Nm\CCrbjDDU3Mh[2WubIOsJGlEPTBiPTCwMlA3QCEQvF2u	NX7ROWtnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW0OVQzPDJpPkG1OFU1OjR{PD;hQi=>
COS	M4jhSWZ2dmO2aX;uJIF{e2G7				M{TjNGlvcGmkaYTpc44hd2ZiaIXtZY4hS0:[MjDlfJBz\XO\|ZXSgbY4h[W[{aXPhckBoemWnbjDtc45s\XliQ1;TJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiYYLhZ4hq\G:waXOgZYNq\C2\|dHnteYxifGWmIGDHSVIheHKxZIXjeIlwdiC2cnXheIVlKDFiaIKgZoVnd3KnIHHyZYNpcWSxbnnjJIFkcWRiY3jhcIxmdmenIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFAvODZ6IN88UU4>	Mo[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl3MkC1O\|MoRjF7NUKwOVc{RC:jPh?=
143982	NEHLN2tHfW6ldHnvckBie3OjeR?=				MoT0TY4hfmm2cn:gbY5pcWKrdH;yfUBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDyc5N1[WeuYX7kbY4hTy:KIIP5cpRp[XOnIEKgLGNQYC1{KTDpckAyPDN7OEKgZ4VtdHNuIFnDOVAhRSByLkC3PUDPxE1w	NHnHUFY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMki3O\|U5PCd-MUK4O\|c2QDR:L3G+
J774	NW[5S414TnWwY4Tpc44h[XO\|YYm=				NXPBUnc2UW5idnn0do8hcW6qaXLpeI9zgSCjY4Tpeol1gSCjZ3HpcpN1KFC{b4P0ZYdt[W6maX6gS{9JKHO7boToZZNmKDJiaX6gcZVzcW6nIFq3O\|Qh[2WubIOsJGlEPTBiPTCwMlA4QSEQvF2u	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh3N{G0PUc,OTV6NUexOFk9N2F-
J774	MnvDSpVv[3Srb36gZZN{[Xl?				M4exdWlvcGmkaYTpc44hd2ZiQ1;YNk1l\XCnbnTlcpQhWEeHMjDwdo9lfWO2aX;uJIlvKEySUz3zeIlufWyjdHXkJI1wfXOnIFq3O\|Qh[2WubIOgZpkhWkmDLDDJR\|UxKD1iMD6wO\|kh\|ryPLh?=	NG\sXmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm1O\|k{OSd-MUm5OVc6OzF:L3G+
osteosarcoma cells	M1vt[WZ2dmO2aX;uJIF{e2G7				NEjxe\|lKdmirYnn0bY9vKG:oIGDyc5N1[WeuYX7kbY4hTy:KIIP5cpRp[XOnIEKgbY4hOTR\|Lkm4MlIh\nKxbTDoeY1idiCxc4Tlc5NiemOxbXGgZ4VtdHNuIFnDOVAhRSByLkC4JO69VS5?	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yOTR4Mkm3Okc,OTF2NkK5O\|Y9N2F-
SF9	MX3GeY5kfGmxbjDhd5NigQ>?				NEHDTHdKdmirYnn0bY9vKG:oIHj1cYFvKEORWEKg[ZhxemW\|c3XkJIlvKHOoOTDj[YxteyxiSVO1NEA:KDBwMEig{txONg>?	NXjKUll[RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMU[yOVI6OTdpPkG2NlUzQTF5PD;hQi=>
RAW264.7	MVXBcpRqcW6obHHtcYF1d3K7IHHzd4F6				M3X3TGFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDQS2UzKHC{b3T1Z5Rqd25uIFnDOVAhRSByLkGg{txONg>?	MnnCQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJyMEC5OFgoRjJ{MECwPVQ5RC:jPh?=
RAW264.7	NGLRXJZHfW6ldHnvckBie3OjeR?=				MUDJcohq[mm2aX;uJI9nKEORWD2yJIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIRm[3KnYYPlJIlvKEySUz3pcoR2[2WmIGDHSVIheHKxZIXjeIlwdixiSVO1NEA:KDBwMUKg{txONg>?	NVLXbZk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzOVM4PDFpPkKzN\|U{PzRzPD;hQi=>
Sf21	NWnFSoxLTnWwY4Tpc44h[XO\|YYm=				NVTHfYNpUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBpfW2jbjDOMZRmem2rbnHsJGhqey22YXfn[YQhS0:[MjDlfJBz\XO\|ZXSgbY4h[mGldXzveolzfXNiaX7m[YN1\WRiU3[yNUBk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hcW5icILvd5Ri\2yjbnTpckBxem:mdXP0bY9vKGK7IHXufplu\SCrbX31co9ie3OjeTygTWM2OCB;IECuNVUh\|ryPLh?=	MkDsQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl\|N{OyO\|EoRjJ7M{ezNlcyRC:jPh?=
Sf21	MlrFSpVv[3Srb36gZZN{[Xl?		NWj5dpNzPSCvaX7z		NWTPUWlYUW6qaXLpeIlwdiCxZjDy[YNwdWKrbnHueEBPNXSncn3pcoFtKEirc{[teIFo\2WmIHj1cYFvKEORWD2yJIV5eHKnc4Pl[EBqdiCEYXP1cI93cXK3czDpcoZm[3SnZDDT[lIyKGOnbHzzJJV{cW6pIHHyZYNpcWSxbnnjJIFkcWRiYYOgd5Vje3S{YYTlJJBz\WmwY4XiZZRm\CCob4KgOUBucW6\|IH\vcIxwf2WmIHL5JJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjCxJIhzNCCLQ{WwJF0hOC5{NjFOwG0v	NH62N4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEK5N\|c6PSd-M{CyPVM4QTV:L3G+
MC9	MWnGeY5kfGmxbjDhd5NigQ>?				M1qyOWlvcGmkaYTpc44hd2ZiUFfGNoFxcGFicILv[JVkfGmxbjDpckBiemGlaHnkc45q[yCjY3nkMZN1cW23bHH0[YQhdW:3c3WgUWM6KGOnbHzzMEBKSzVyIE2gNE4{KM7:TT6=	M33uWFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm4NVUxLz5zOES5PFE2ODxxYU6=
MC9	M1GzOGZ2dmO2aX;uJIF{e2G7				M1ewPWlvcGmkaYTpc44hd2ZiUFfGNoFteGijIIDyc4R2[3Srb36gbY4hdW:3c3WgUWM6KGOnbHzzMEBKSzVyIE2gNE41KM7:TT6=	M2\IelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm4NVUxLz5zOES5PFE2ODxxYU6=
293E	NELSfpNHfW6ldHnvckBie3OjeR?=				NIfNR4VKdmirYnn0bY9vKG:oIHj1cYFvKG2rY4Lvd49u[WxiUFfFV\|Eh\XiycnXzd4VlKGmwIEK5N2Uh[2WubIOgZpkhVENxTWOvUXMh[W6jbInzbZMtKEmFNUCgQUAxNjR{NTFOwG0v	Mnu0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ4NUOxPFAoRjJ4NkWzNVgxRC:jPh?=
SF9	NHjqdHhHfW6ldHnvckBie3OjeR?=		NWSz[WZsOTVibXnudy=>		NV\x[lJ{UW6qaXLpeIlwdiCxZjDmeYxtKGynbnf0bEBz\WOxbXLpcoFvfCCqdX3hckBPNXSncn3pcoFtKEeVVD30ZYdo\WRiSFTBR\|Yh\XiycnXzd4VlKGmwIHLhZ5Vtd3[rcoXzJIlv\mWldHXkJJNnQSClZXzsd{B2e2mwZzDCc4MuVHm\|LTjBZ{kuSU2FIHHzJJN2[nO2cnH0[UBxemWrbnP1ZoF1\WRiZn;yJFE2KG2rboOg[o9tdG:5ZXSgZpkhe3Wkc4TyZZRmKGGmZHn0bY9vKG2nYYP1doVlKGGodHXyJFYxKG2rboOgZpkh\my3b4Lld4NmdmOnIHHzd4F6NCCLQ{WwJF0hOC54NEOg{txONg>?	NVXlcVFURGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm1NFAyOzBpPkK5OVAxOTNyPD;hQi=>
HT-29	M1LFU2N6fG:2b4jpZ4l1gSCjc4PhfS=>		MUm0PEBpenN?		MmT1R5l1d3SxeHnjbZR6KGGpYXnud5QhS0:[LUKgdI9{cXSrdnWgbJVu[W5iSGStNlkh[2WubIOgeJJidnOoZXP0[YQhf2m2aDDDSFQ1fj[\|aGLORUBie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA1QCCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOC55IN88UU4>	MV:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
SF9	MmPHSpVv[3Srb36gZZN{[Xl?		NVHyfHVyOTVibXnudy=>		M3rxO2lvcGmkaYTpc44hd2ZicnXjc41jcW6jboSgUIVqe2ivYX7pZUBld26xdnHubUBkcGGpYYPpJIJmfGFvY3HyZo9vcWNiYX7ofYRz[XOnIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCrboPlZ5QhW2Z7IHPlcIx{KGmwY4XiZZRm\CCob4KgNVUhdWmwczDwdolweiC2bzD0[ZN1cW6pIHL5JJN1d3CyZXSg[oxwfyCFT{KgbJllemG\|ZTDhd5NigSxiS3mgQUAxNjdyNTFOwG0v	M2PqNVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|OUe3PVYxLz5{M{m3O\|k3ODxxYU6=
HCA-7	M2\jSmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M2\aflQ5KGi{cx?=		MUXDfZRwfG:6aXPpeJkh[WejaX7zeEBEV1hvMjDwc5NqfGm4ZTDoeY1idiCKQ1GtO{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIFPEOFR3PnOqUl7BJIF{e2W\|c3XkJIF{KGe{b4f0bEBqdmirYnn0bY9vKGGodHXyJFQ5KGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUAxNjd3IN88UU4>	MoniQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUW3PFcoRjJ2Mkm1O\|g4RC:jPh?=
HepG2	M3fQTmFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NFHOVXA1QCCqcoO=		MVHBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEincFeyJINmdGy\|IHnuZ5Vj[XSnZDDmc5IhPDhiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDBwN{[g{txONg>?	NGDSTHI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NkO0OlM3Pyd-Mk[zOFY{Pjd:L3G+
SF9	NFrrZnZHfW6ldHnvckBie3OjeR?=		M1XhT\|E2KG2rboO=		NHnxdoZKdmirYnn0bY9vKG:oIH\1cIwhdGWwZ4ToJJJm[2:vYnnuZY51KGi3bXHuJGMufGW{bXnuZYwhTkyDRz;IbZMufGGpZ3XkJGhFSUNzIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CC\|ZkmgZ4VtdHNidYPpcochSm:lLVz5d{0pSWNrLVHNR{BieyC\|dXLzeJJifGVicILlbY5kfWKjdHXkJIZweiBzNTDtbY5{KG[xbHzve4VlKGK7IIP1ZpN1emG2ZTDh[IRqfGmxbjDt[YF{fXKnZDDh[pRmeiB4MDDtbY5{KGK7IH\seY9z\XOlZX7j[UBie3NuIFnDOVAhRSBzLkG4OUDPxE1w	M{jCW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NUCwNVMxLz5{OUWwNFE{ODxxYU6=
RAW264.7	MnLURY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?		MmC1NVghcHK\|		M2fWTWFvfGmrbn\sZY1u[XSxcomgZYN1cX[rdImgbY4hdW:3c3WgVmFYOjZ2LkegZ4VtdHNiYYPz[ZN{\WRiYYOgbY5pcWKrdHnvckBw\iCOUGOtbY5lfWOnZDDUUmYu[WyyaHGgd4VkemW2aX;uJIFnfGW{IEG4JIhzeyCkeTDzZY5lf2mlaDDFUGlUSSxiSVO1NEA:KDFwMkig{txONg>?	MnXnQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{m0OFEoRjJ2Nke5OFQyRC:jPh?=
APC10.1	MVTDfZRwfG:6aXPpeJkh[XO\|YYm=		M33ZVFQ5KGi{cx?=		M1XxcGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KEORWD2yJJBwe2m2aY\lJI1wfXOnIFHQR\|ExNjFiY3XscJMhfHKjboPm[YN1\WRid3n0bEBETDR2dk\zbHJPSSCxdnXy[ZhxemW\|c3nu[{BJSVNvMjDhd5Nme3OnZDDhd{Boem:5dHigbY5pcWKrdHnvckBi\nSncjC0PEBpenNiYomgUXRVKGG\|c3H5MEBKSzVyIE2gNU4{KM7:TT6=	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
RAW264.7	M4HoVGFvfGmrbn\sZY1u[XSxcomgZZN{[Xl?		MnXaN\|AhdWmwcx?=		MXLBcpRqcW6obHHtcYF1d3K7IHHjeIl3cXS7IHnuJI1wfXOnIGLBW\|I3PC55IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhVFCVLXnu[JVk\WRibnn0dolkKG:6aXTlJJBzd2S3Y4Tpc44heHKnaX7jeYJifGWmIH\vdkA{OCCvaX7zJIZwdGyxd3XkJIJ6KEySUzDzeIlufWyjdHnvckBu\WG\|dYLl[EBi\nSncjCyOEBpenNiYomgS5Jq\XO\|IHHzd4F6NCCLQ{WwJF0hOS54IN88UU4>	MYm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjR2NEC5PEc,OjZ2NESwPVg9N2F-
COS	MkPKSpVv[3Srb36gZZN{[Xl?				MYDJcohq[mm2aX;uJI9nKGi3bXHuJIN6[2yxb4j5[4Vv[XOnLUGg[ZhxemW\|c3XkJIlvKEORUzDj[YxteyxiSVO1NEA:KDFwNki5JO69VS5?	M1rVflxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF3NEW0NlQzLz5zNUS1OFI1OjxxYU6=
COS	M1LvPGZ2dmO2aX;uJIF{e2G7				NFLWc3FKdmirYnn0bY9vKG:oIHj1cYFvKEORWEGg[ZhxemW\|c3XkJIlvKGGocnnjZY4h\3KnZX6gcY9vc2W7IFPPV{Bk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIHHyZYNpcWSxbnnjJIFkcWRvc4TpcZVt[XSnZDDQS2UzKHS{ZXH0[YQhOSCqcjDi[YZwemViYYLhZ4hq\G:waXOgZYNq\CClaHHscIVv\2ViYomg[Y57gW2nIHntcZVvd2G\|c3H5MEBKSzVyIE2gNU43QDlizszNMi=>	M4X0eVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NUKwOVc{Lz5zOUWyNFU4OzxxYU6=
RAW264.7	MUXBcpRqcW6obHHtcYF1d3K7IHHzd4F6		M2XyN\|E5KGi{cx?=		NH7sbmlCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIlvKG2xdYPlJHJCXzJ4ND63JINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2ZiTGDTMYlv\HWlZXSgcol1emmlIH;4bYRmKHC{b3T1Z5Rqd25iYX\0[ZIhOThiaILzJIJ6KGe{aXXzd{Bz\WGldHnvckBidmGueYPpd{whUUN3MDC9JFEvQDRizszNMi=>	NH7YfWE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NE[3PVQ1OSd-MkS2O\|k1PDF:L3G+
HCA-7	NYnYdHdTS3m2b4TvfIlkcXS7IHHzd4F6		MX[xPEBpenN?		NXm5dXpuS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEODLUegZ4VtdHNiYYPz[ZN{\WRiYYOg[IVkemWjc3WgbY4h[2WubDDzeZJ3cX[jbDDh[pRmeiBzODDodpMh[nliTWTTJIF{e2G7LDDJR\|UxKD1iMjFOwG0v	MoOxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUe3NlEoRjJ\|NUG3O\|IyRC:jPh?=
A549	Ml3IRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MXm0PEBpenN?		NEX5ZpRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMj6xOUDPxE1w	Mn;nQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NE[zOlcoRjJ4M{S2N\|Y4RC:jPh?=
Escherichia coli Arctic cells	MXrGeY5kfGmxbjDhd5NigQ>?		NGS4fYsyPSCvaX7z		MUPJcohq[mm2aX;uJI9nKHKnY3;tZolv[W62IGP0doVxfG:lb3PjeZMhdXW2YX7zJHVCOTV7IHLleIEu[2G{Yn;ubYMh[W6qeXTyZZNmKGW6cILld5Nm\CCrbjDFd4Np\XKrY3jpZUBkd2yrIFHyZ5Rq[yClZXzsd{BxemWrbnP1ZoF1\WRiZn;yJFE2KG2rboOgZpkhe3SxcIDl[EBndG:5IFPPNkBpgWS{YYPlJIF{e2G7LDDLbUA:KDJwNEK1JO69VS5?	M3LxSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3OUGzNVk6Lz5{NUmxN\|E6QTxxYU6=
HT-29	MnnzR5l1d3SxeHnjbZR6KGG\|c3H5		M4[wSFE5KGi{cx?=		NIS2SWVEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBJXC1{OTDj[YxteyCjc4Pld5Nm\CCjczDk[YNz\WG\|ZTDpckBk\WyuIIP1dpZqfmGuIHHmeIVzKDF6IHjyd{BjgSCPVGOgZZN{[XluIFnDOVAhRSB\|IN88UU4>	NX;SWGRDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVc4OjFpPkKzOVE4PzJzPD;hQi=>
J774	NGjGUXdHfW6ldHnvckBie3OjeR?=				MWTJcohq[mm2aX;uJI9nKEORWEGgbY4hdW:3c3WgTlc4PCClZXzsd{Bie3Onc4Pl[EBieyCjcnHjbIlld26rYzDhZ4llNWmwZIXj[YQhWEeHMjDs[ZZmdHNiYomgdoFlcW9iaX3teY5w[XO\|YYmsJGlEPTBiPTCzMlch\|ryPLh?=	NG\YZ2Y9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{mxOVg2PCd-MUe5NVU5PTR:L3G+
J774	MXPGeY5kfGmxbjDhd5NigQ>?		M37xZVE2KG2rboO=		MmDFTY5pcWKrdHnvckBw\iCFT2ixJIlvKGG{YXPobYRwdmmlIHHjbYQue3SrbYXsZZRm\CCvb4Xz[UBLPzd2IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4YhWEeHMjDwdo9lfWO2aX;uJIFnfGW{IEG1JI1qdnNiYomgdoFlcW:rbX31co9ie3OjeTygTWM2OCB;IEOuO{DPxE1w	NVHsfVc6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi3OVI6PTdpPkG4O\|UzQTV5PD;hQi=>
J774	NUm2XI5LTnWwY4Tpc44h[XO\|YYm=		M2rNTVE2KG2rboO=		NIf3cWpKdmirYnn0bY9vKG:oIFPPXE0yNW2nZHnheIVlKFCJRUKgdJJw\HWldHnvckBqdiCjcnHjbIlld26rYzDhZ4llNXO2aX31cIF1\WRibX;1d4UhUjd5NDDj[YxteyCrbnP1ZoF1\WRiZn;yJFE2KG2rboOgdJJqd3JidH:gZZJi[2irZH;ubYMh[WOrZD3jbIFtdGWwZ3WgZpkhemGmaX;pcY12dm:jc4PhfUwhUUN3MDC9JFMvQDRizszNMi=>	MVi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl7MkG3Okc,OjF7OUKxO\|Y9N2F-
J774	MXrGeY5kfGmxbjDhd5NigQ>?		MVyxOUBucW6\|		Mkn2TY5pcWKrdHnvckBw\iCFT2ixJIlvKG2xdYPlJGo4PzRiY3XscJMhfXOrbnegZZJi[2irZH;ubYMh[WOrZDDhd{B{fWK\|dILheIUh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBRT0V{IIDyc4R2[3Srb36gbY5kfWKjdHXkJIZweiBzNTDtbY5{KHC{aX;yJJRwKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA{OCCvaX7zJIJ6KHKjZHnvbY1ufW6xYYPzZZktKEmFNUCgQUA{Njh2IN88UU4>	NUCyOXUxRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFA1PDRpPkKzOlgxPDR2PD;hQi=>
APC10.1	MnXWR5l1d3SxeHnjbZR6KGG\|c3H5		NIqzWYQyQCCqcoO=		MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W\|ZTDBVGMyOC5zIHPlcIx{KGG\|c3Xzd4VlKGG\|IHTlZ5Jm[XOnIHnuJINmdGxic4Xyeol3[WxiYX\0[ZIhOThiaILzJIJ6KE2WUzDhd5NigSxiSVO1NEA:KDRwMjFOwG0v	M4jxeFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
B16F10	MlLrRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MonQNlQhcHK\|		M17qV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQkG2SlExKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0MlU3KM7:TT6=	NV;CblBoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW4OlYzPDBpPkK1PFY3OjRyPD;hQi=>
HCA-7	NU\vfIwxS3m2b4TvfIlkcXS7IHHzd4F6				NXXlRlh2S3m2b4TvfIlkcXS7IHHnZYlve3RiQ1;YMVIheG:\|aYTpeoUhcHWvYX6gTGNCNTdiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgR4VtdFSrdHXyMVk3KEGTdXXveZMh[XO\|YYmsJGlEPTBiPTC0Mlkh\|ryPLh?=	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
SH-SY5Y	M2PWRWFvfGmwZYXyc5RwgGmlaYT5JIF{e2G7		Mn[wO\|IhcHK\|		NYrDSGN1SW62aX7leZJwfG:6aXPpeJkhcW5iaIXtZY4hW0hvU2m1XUBk\WyuczDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKGi3bXHuJHRJWDFiY3XscEB{fXCncn7heIFvfC2rbnT1Z4VlKGO7dH;0c5hq[2m2eTDjc41xd3WwZDDwdoV1emWjdHXkJFI1KHSxIES4JIhzeyC2bzDUTHAyKGOnbHzzJI1m[XO3cnXkJIFnfGW{IEeyJIhzeyCxZjDzeZBmem6jdHHueEBi\GSrdHnvckwhUUN3MDC9JFUh\|ryPLh?=	NYnqRZQzRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|g4PzBpPkKwNVM5PzdyPD;hQi=>
THP1	MUnO[ZVzd3C{b4TlZ5RqfmViYYPzZZk>		MnXLO\|IhcHK\|		MWTO[ZVzd3C{b4TlZ5RqfmViYXP0bZZqfHliYXfhbY5{fCCOUGOgZY5lKEmITj3nZY1u[S2\|dHnteYxifGWmIH7leZJwfG:6aX6gdJJw\HWldHnvckBqdiCqdX3hckBVUFBzIHPlcIwh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBVUFBzIHPlcIwhe2WlcnX0bY9vNWmwZIXj[YQhfG:6aXPpeJkhfG9iaIXtZY4hW0hvU2m1XUBk\WyuczDh[pRmeiB5MjDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNTFOwG0v	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyOUW4PUc,OjB4MEm1PFk9N2F-
U-937	MmG2SpVv[3Srb36gZZN{[Xl?				MoX3TY5pcWKrdHnvckBw\iCScn;zeIFodGGwZHnuJGcwUCC\|eX70bIF{\SBzIHnuJHUuQTN5IHPlcIx{KG[{b32gbJVu[W5iaHnzeIlw[3m2aXOgcJlueGixbXGsJGlEPTBiPTC1MlEh\|ryPLh?=	NXzFN\|B5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUG0OlI6PzZpPkGxOFYzQTd4PD;hQi=>
U-937	MkDuSpVv[3Srb36gZZN{[Xl?				M1\xZWlvKH[rdILvJIlvcGmkaYTvdpkh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQdo9{fGGpbHHu[IlvKEdxSDDzfY51cGG\|ZTCxJEhEV1hvMTmgbY4hXS17M{egZ4VtdHNuIFnDOVAhRSB3LkGg{txONg>?	NIK3T4M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMki3O\|U5PCd-MUK4O\|c2QDR:L3G+
J774	MUPGeY5kfGmxbjDhd5NigQ>?				MYLJckB3cXS{bzDpcohq[mm2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgVJJwe3SjZ3zhcoRqdiCJL1igd5lvfGijc3WgNUBqdiCvdYLpcoUhUjd5NDDj[YxteyxiSVO1NEA:KDVwMTFOwG0v	MXO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTh3N{G0PUc,OTV6NUexOFk9N2F-
J774	MmTCSpVv[3Srb36gZZN{[Xl?				NETQUJNKdmirYnn0bY9vKG:oIFPPXFEu\GWyZX7k[Y51KFCJRUKgdJJw\HWldHnvckBqdiCOUGOtd5RqdXWuYYTl[EBud3W\|ZTDKO\|c1KGOnbHzzJIJ6KFKLQTygTWM2OCB;IEWuNUDPxE1w	NIrkOFg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUm1O\|k{OSd-MUm5OVc6OzF:L3G+
HT-29	MV;DfZRwfG:6aXPpeJkh[XO\|YYm=				NFvwb4FEgXSxdH;4bYNqfHliYXfhbY5{fCCFT2itNkBxd3OrdHn2[UBpfW2jbjDIWE0zQSClZXzsd{Bie3Onc4Pl[EBieyCpcn;3eIghcW6qaXLpeIlwdiCkeTDD[YxtXGm2ZYKtPVYhSVG3ZX;1d{Bie3OjeTygTWM2OCB;IEWuO{DPxE1w	M2\CeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2Mkm1O\|g4Lz5{NEK5OVc5PzxxYU6=
MCF7	M4XsOGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		M13qSlI1KGi{cx?=		NILtdHdCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEWuPVQh\|ryPLh?=	NHj6Zms9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUi2OlI1OCd-MkW4OlYzPDB:L3G+
APC10.1	MYPGeY5kfGmxbjDhd5NigQ>?		Ml;3NVghcHK\|		MoDjTY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OEBidnSrZ3XuJJZiemmjboSg[ZhwdiB4IHHjeIl3cXS7IHnuJI1wfXOnIFHQR\|ExNjFiY3XscJMh\XiycnXzd4lv\yCKYYOyJIF{e2W\|c3XkJIF{KGSnY4LlZZNmKGmwIHPlcIwhe3W{dnn2ZYwh[W[2ZYKgNVghcHK\|IHL5JG1VWyCjc4PhfUwhUUN3MDC9JFYh\|ryPLh?=	Ml3rQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUe3NlEoRjJ\|NUG3O\|IyRC:jPh?=
MCF7	NYL5e4MzSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NEf0OFE1QCCqcoO=		NXy4dpBJSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIlv[3WkYYTl[EBnd3JiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IE[uPFgh\|ryPLh?=	MYC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPjN2NkO2O{c,OjZ\|NE[zOlc9N2F-
SW480	MXnDfZRwfG:6aXPpeJkh[XO\|YYm=				NWrHR3JOS3m2b4TvfIlkcXS7IHHnZYlve3RiQ1;YMVIhdmWpYYTpeoUhcHWvYX6gV3c1QDBiY3XscJMh[XO\|ZYPz[YQh[XNiZ4Lve5RpKGmwaHnibZRqd25iYomgR4VtdFSrdHXyMVk3KEGTdXXveZMh[XO\|YYmsJGlEPTBiPTC2Mlkh\|ryPLh?=	NYj2WmlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSyPVU4QDdpPkK0Nlk2Pzh5PD;hQi=>
HeLa	MljVRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		M3TDTlI1KGi{cx?=		M4fGSGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz6zOUDPxE1w	MnrpQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV6Nk[yOFAoRjJ3OE[2NlQxRC:jPh?=
HeLa	NFLmNXhCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		MmrZOFghcHK\|		NF7ES41CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgbY5kfWKjdHXkJIZweiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz61OUDPxE1w	MkH2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ\|NE[zOlcoRjJ4M{S2N\|Y4RC:jPh?=
HeLa	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MnntNlQhcHK\|		M{\HeWFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iSHXMZUBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iNz63PUDPxE1w	MmC1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEmzN\|EoRjJ5M{S5N\|MyRC:jPh?=
HepG2	MXHBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		Mm\GNlQhcHK\|		MoK4RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKZYDHNkBk\WyuczDh[pRmeiB{NDDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUCuNFMh\|ryPLh?=	Mmn0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|NEmzN\|EoRjJ5M{S5N\|MyRC:jPh?=
APC10.1	MlPIR5l1d3SxeHnjbZR6KGG\|c3H5				MoPwR5l1d3SxeHnjbZR6KGGpYXnud5QhS0:[LUKgdI9{cXSrdnWgcY92e2ViQWDDNVAvOSClZXzsd{BwfmW{ZYjwdoV{e2mwZzDIRXMuOiCjc4Pld5Nm\CCjczDndo94fGhiaX7obYJqfGmxbjDifUBE\WyuVHn0[ZIuQTZiQWH1[Y92eyCjc4PhfUwhUUN3MDC9JFE{NjRizszNMi=>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
CHO	NWfkU5VITnWwY4Tpc44h[XO\|YYm=				NYX3NndXUW6qaXLpeIlwdiCxZjDDU3gyKGW6cILld5Nm\CCrbjDDTG8h[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDhdoFkcGmmb37pZ{Bi[2mmLYP0bY12dGG2ZXSgVGdGOiCycn;keYN1cW:wIHL5JIVvgnmvZTDpcY12dm:jc4PhfUwhUUN3MDC9JFE{NjVizszNMi=>	NVTNV21FRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1OlYzQTBpPkG1OVY3OjlyPD;hQi=>
B16F10	MU\BcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		M1vteFI1KGi{cx?=		M2O5SGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQkG2SlExKGOnbHzzJIFnfGW{IEK0JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOE4{PiEQvF2u	MW[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN2OUOzNUc,Ojd\|NEmzN\|E9N2F-
A549	M4fIdmFvfGm2dX3vdkBie3OjeR?=		NVv6bFQ{PDhiaILz		M1OyR2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFG1OFkh[2WubIOgZZN{\XO\|ZXSgZZMhcW6qaXLpeIlwdiCxZjDj[YxtKHC{b3zp[oVz[XSrb36gZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG1MlYh\|ryPLh?=	M4f0TVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{WzO\|QyLz5{M{O1N\|c1OTxxYU6=
A549	M33FemFvfGmycn;sbYZmemG2aY\lJIF{e2G7		MXuyOEBpenN?		MYnBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEF3NEmgZ4VtdHNiYX\0[ZIhOjRiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDF3Lk[0JO69VS5?	M{DFOVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ5M{S5N\|MyLz5{N{O0PVM{OTxxYU6=
HeLa	NUfHd25JSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		MoezOFghcHK\|		NGT2Uo1CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjlUIEh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEG1MlY6KM7:TT6=	NFLtT4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzNVY2Oid-M{CwN\|E3PTJ:L3G+
A549	NH;BTIJCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=		NVf6do9CPDhiaILz		NV\vWIxUSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDBOVQ6KGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxOk4xQCEQvF2u	Ml36QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzByM{G2OVIoRjNyMEOxOlUzRC:jPh?=
NCI60	M4TpfWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7		M3LLd\|Q5KGi{cx?=		MlHMS5Jwf3SqIHnubIljcXSrb36gc4YhcHWvYX6gUmNKPjBiY3XscJMh[W[2ZYKgOFghcHK\|IHL5JJN2dG[xcnjv[IFucW6nIFKgZZN{[XluIFfJOVAhRSBzNz61JO69VS5?	M1rLd\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyM{i3PFE2Lz5{MEO4O\|gyPTxxYU6=
HCA-7	NU\NPINwTnWwY4Tpc44h[XO\|YYm=		M2DWRVE5KGi{cx?=		M4rXdmlvcGmkaYTpc44hd2ZiaInhcJVzd26jbj3pcoR2[2WmIFPEOFQh[W62aXflckB3[XKrYX70JIV5d25iNjDhZ5Rqfmm2eTDpckBpfW2jbjDIR2EuPyClZXzsd{BmgHC{ZYPzbY5oKEijc{KgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iY3XscEB{fXK4aY\hcEBi\nSncjCxPEBpenNiYomgUXRUKGG\|c3H5MEBKSzVyIE2gNVcvPSEQvF2u	M{nmXlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
HT-29	Mmn1SpVv[3Srb36gZZN{[Xl?		M1zsS\|E5KGi{cx?=		NXLZT5FsUW6qaXLpeIlwdiCxZjDofYFtfXKxbnHuMYlv\HWlZXSgR2Q1PCCjboTp[4VvKH[jcnnhcpQh\XixbjC2JIFkfGm4aYT5JIlvKGi3bXHuJGhVNTJ7IHPlcIx{KGW6cILld5NqdmdiSHHzNkBie3Onc4Pl[EBieyCmZXPy[YF{\SCrbjDj[YxtKHO3co\peoFtKGGodHXyJFE5KGi{czDifUBOXFNiYYPzZZktKEmFNUCgQUAyQC5\|IN88UU4>	NWP2Z\|lkRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1NVc4OjFpPkKzOVE4PzJzPD;hQi=>
platelet	M{jGNGZ2dmO2aX;uJIF{e2G7				M2DXWWlvcGmkaYTvdpkh\W[oZXP0JI9vKHC{b3T1Z5Rqd25ib3[gZ5lkdG:xeInn[Y5ie2VvMTCoR29ZNTFrIITodo9u[m:6YX7lJGIzKCiWWFKyLUBqdiCqdX3hckBxdGG2ZXzleEBk\WyuczygTWM2OCB;IEG5JO69VS5?	NXfwRppMRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUC4NlE4OTZpPkGwPFIyPzF4PD;hQi=>
B16F10	NXX3OYpkSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		NWjiWmtuPDhiaILz		MXXBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IH3veZNmKEJzNl[xNEBk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJIF{e2G7LDDJR\|UxKD1iMUmuNVUh\|ryPLh?=	NGPmZmU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MECzNVY2Oid-M{CwN\|E3PTJ:L3G+
MDA231	M2LTfWFvfGmycn;sbYZmemG2aY\lJIF{e2G7				MoryRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCPRFGyN\|Eh[2WubIOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOjJwN{mg{txONg>?	NX60N4FCRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
MCF7	NUH4eVR4SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4HmOlQ5KGi{cx?=		NFn2OIJCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlch[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IEK2Mlc5KM7:TT6=	M1K4PVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMEOxOlUzLz5\|MECzNVY2OjxxYU6=
HCT116	MXvBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?				NFiwTYVCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjDWFEyPiClZXzsd{BjgSCPVGSgZZN{[XluIFnDOVAhRSB{OT61OEDPxE1w	MmTZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOzB{MU[4OFgoRjNyMkG2PFQ5RC:jPh?=
MCF7	M1vQWWFvfGmycn;sbYZmemG2aY\lJIF{e2G7				NX:1XZpTSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDNzLkK4JO69VS5?	M2HzZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzNyMkG2PFQ5Lz5\|MEKxOlg1QDxxYU6=
LNCAP	M4XWUmN6fG:2b4jpZ4l1gSCjc4PhfS=>		M1zvXlczKGi{cx?=		NYKzTI5VS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hVE6FQWCgZ4VtdHNiYYPz[ZN{\WRiYYOgZ4VtdCCpcn;3eIghcW6qaXLpeIlwdiCjZoTldkA4OiCqcoOgZpkhVVSWIHHzd4F6NCCLQ{WwJF0hOzJwNjFOwG0v	M4LGfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ6MEW3OFA4Lz5{OEC1O\|QxPzxxYU6=
BL21(DE3)	NYfvNI97TnWwY4Tpc44h[XO\|YYm=		MmDjNVUhdWmwcx?=		MU\Jcohq[mm2aX;uJI9nKEeVVD30ZYdo\WRiTXHsZZN{\XqrYTDncI9jd3OjIFHUR2MhQTZ6MEevR2JUKDd7Nk[gUWcuS0FiZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSiGRUOpJINmdGy\|IIDy[Ylv[3WkYYTl[EBnd3JiMUWgcYlveyCvZXHzeZJm\CCob4KgNVAhfG9iMUCwJJNm[yCkeTDzeI9xeGWmLX\sc5chdWW2aH;kMEBMcSB;IEO0Mlgh\|ryPLh?=	NXnDXXk1RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK0NlQzOzlpPkKyOFI1OjN7PD;hQi=>
HeLa	NIL1U\|BCdnSrcILvcIln\XKjdHn2[UBie3OjeR?=				NX3QdIE1SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDN4LkC4JO69VS5?	NYnBc29JRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
MDA-MB-231	M2OycmN6fG:2b4jpZ4l1gSCjc4PhfS=>		MnTEOFghcHK\|		M2HZZmN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1FSS2PQj2yN\|Eh[2WubIOgZYZ1\XJiNEigbJJ{KGK7IF3UV{Bie3OjeTygTWM2OCB;IESwJO69VS5?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjd6MEm2NUc,OjJ5OEC5OlE9N2F-
MCF7	MlfYRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		MmS2OFghcHK\|		M1zENGFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{Bk\WyuczDh[pRmeiB2ODDodpMh[nliTWTUJINwdG:{aX3leJJq[yCjc4PhfUwhUUN3MDC9JFQxNjhizszNMi=>	NH:5d5U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MkCwNFk1QCd-MkKwNFA6PDh:L3G+
MCF7	MUnBcpRqfHWvb4KgZZN{[Xl?		NGTyVZY1QCCqcoO=		NGHoTIhCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNR2Y4KGOnbHzzJIF{e2W\|c3XkJIF{KGmwaHnibZRqd25ib3[gZ4VtdCCycn;sbYZmemG2aX;uJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTC0NE45KM7:TT6=	M2W5TlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{WzO\|QyLz5{M{O1N\|c1OTxxYU6=
Caco2	NYHlPZk6SW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=				MoH2RY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCFYXPvNkBk\WyuczDifUBOXFRiYYPzZZktKEmFNUCgQUA1Oi55NDFOwG0v	NYXtcVExRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{CyNVY5PDhpPkOwNlE3QDR6PD;hQi=>
HCT116	M4j6d2FvfGmlYX7j[ZIh[XO\|YYm=		MlTQO\|IhcHK\|		M2G2Z2FvfGmlYX7j[ZIh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ{NjNizszNMi=>	M{TQPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNke4PVcyLz5{MU[3PFk4OTxxYU6=
L1210	NWPGeFFJS3m2b4TvfIlkcXS7IHHzd4F6		NWjPR2hDPzJiaILz		M1rQNWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGwyOjFyIHPlcIx{KGGodHXyJFczKGi{czDifUBOXFRiYYPzZZktKEmFNUCgQUA1PCEQvF2u	NYn0UXpiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OVE{QTdpPkKwOFUyOzl5PD;hQi=>
HT-29	Mnf1R5l1d3SxeHnjbZR6KGG\|c3H5				M2DJXGN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGhVNTJ7IHPlcIx{KGK7IF3UWEBie3OjeTygTWM2OCB;IES1MlUh\|ryPLh?=	M1r3R\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyOEC0NVk4Lz5{MEiwOFE6PzxxYU6=
PC3	M{XjdmFvfGmlYX7j[ZIh[XO\|YYm=				MmjDRY51cWOjbnPldkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczygS2k2OCB;IES3JO69VS5?	Mk[zQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh{NkKzNFkoRjF6Mk[yN\|A6RC:jPh?=
PC3	MWLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MoLmO\|IhcHK\|		NXzhN4s5SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBidmS{b3flck1qdmSncHXu[IVvfCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCC2ZYP0MEBKSzVyIE2gOFch\|ryPLh?=	NUPHb3Y4RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUW1OlYzQTBpPkG1OVY3OjlyPD;hQi=>
PC3	M1rWUGFvfGmycn;sbYZmemG2aY\lJIF{e2G7		NVTsNnBJPzJiaILz		NUH2dodlSW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDQR\|Mh[2WubIOgZYZ1\XJiN{KgbJJ{KGK7IF3UWEBie3OjeTygTWM2OCB;IES4JO69VS5?	NV\qZ\|V{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUe5N\|c6PzJpPkG3PVM4QTd{PD;hQi=>
PC3	NInMdGdHfW6ldHnvckBie3OjeR?=		NEf2bVYzKGi{cx?=		MlfzTY5pcWKrdHnvckBw\iCSRFuxMY1m\GmjdHXkJGFsfCCjY4TpeoF1cW:wIHnuJIh2dWGwIGDDN{Bk\WyuczDh[pRmeiB{IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{NCCLQ{WwJF0hPDhizszNMi=>	NVzxOJVnRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO3N\|UzQDFpPkKzO\|M2OjhzPD;hQi=>
PC3	M1vvc2N6fG:2b4jpZ4l1gSCjc4PhfS=>		NX7GPIJSPzJiaILz		NGf3R3dEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBRSzNiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ5NjVizszNMi=>	MmexQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NUGzPVcoRjJyNEWxN\|k4RC:jPh?=
MCF7	NY\ESlNlSW62aYDyc4xq\mW{YYTpeoUh[XO\|YYm=		M4\OUlczKGi{cx?=		MY\BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkegZ4VtdHNiYX\0[ZIhPzJiaILzJIJ6KE2WVDDhd5NigSxiSVO1NEA:KDR7Lk[2JO69VS5?	MX:8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTF7MUWwNkc,OjlzOUG1NFI9N2F-
A549	M{T2VGZ2dmO2aX;uJIF{e2G7				MlP0TY5pcWKrdHnvckBw\iCFT2iyMYRmeGWwZHXueEBRT0V{IIDyc4R2[3Srb36gbY4hUUxzQjDzeIlufWyjdHXkJIh2dWGwIFG1OFkh[2WubIOgbY4heHKnc3XuZ4Uhd2ZiYYLhZ4hq\G:waXOgZYNq\A>?	NILHTGs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES5PFE2OCd-MUi0PVgyPTB:L3G+
A549	MkOxSpVv[3Srb36gZZN{[Xl?				M3nkfmlvcGmkaYTpc44hd2ZiQ1;YNk1l\XCnbnTlcpQhWEeHMjDwdo9lfWO2aX;uJIlvKEmOMVKgd5RqdXWuYYTl[EBpfW2jbjDBOVQ6KGOnbHzz	M{TlVlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6NEm4NVUxLz5zOES5PFE2ODxxYU6=
A549	NEeyOYZHfW6ldHnvckBie3OjeR?=	NG\1W\|c2KHWP			MljQTY5pcWKrdHnvckBw\iCvUFfFV\|EhcW5iaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLUGtZoV1[S2rbnT1Z4VlKFCJRUKg[o9zdWG2aX;uJIF1KDVidV2gZpkh[2WubD3pcpRi[3RiYYPzZZk>	M3jLWVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEWzO\|UyLz5zOUC1N\|c2OTxxYU6=
A549	M4q0VGZ2dmO2aX;uJIF{e2G7	M16xXFUhfU1?	NELrSGUyOCCvaX7z		M2f5UWlvcGmkaYTpc44hd2ZibWDHSXMyKGmwIFnMNU1j\XSjIHnu[JVk\WRiaIXtZY4hSTV2OTDj[YxteyCjc4Pld5Nm\CCjczDQS2UzKHC{b3T1Z5Rqd25iYYSgOUB2VSCycnXpcoN2[mG2ZXSg[o9zKDFyIH3pcpM>	M4Ti[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7OEi0NFEyLz5zOUi4OFAyOTxxYU6=
PANC1	M1rKPGZ2dmO2aX;uJIF{e2G7	NYOyU3hnOjVidH:gOVAhVQ>?	MYezNEBucW6\|		MWPJcohq[mm2aX;uJI9nKEmOLU[tbY5lfWOnZDDTWGFVOyCyaH;zdIhwenmuYYTpc44hcW5iaIXtZY4hWEGQQ{GgZ4VtdHNiYYSgNlUhfG9iNUCgUUBxemW2cnXheIVlKDJiaILzJJBzcW:{IITvJGlNNTZiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDNyIH3pcpM>	Mn7xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF4N{i5O\|EoRjJzNke4PVcyRC:jPh?=
HT29	MW\GeY5kfGmxbjDhd5NigQ>?	MVixNEB2VQ>?			MkLNTY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OEBidnSrZ3XuJJZiemmjboSg[ZhwdiB4IHHjeIl3cXS7IHnuJIh2dWGwIFjUNlkh[2WubIOgZZN{\XO\|ZXSgZZMh\GWlcnXhd4UhcW5iNT3MU3gh\XiycnXzd4lwdiCjdDCxNEB2VQ>?	MnHlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN3MUe3NlEoRjJ\|NUG3O\|IyRC:jPh?=
HT29	MWDGeY5kfGmxbjDhd5NigQ>?	NVPKdXVjOTBidV2=			NVL3XoRYUW6qaXLpeIlwdiCxZjDofYFtfXKxbnHuMYlv\HWlZXSgR2Q1PCCjboTp[4VvKH[jcnnhcpQh\XixbjC2JIFkfGm4aYT5JIlvKGi3bXHuJGhVOjliY3XscJMh[XO\|ZYPz[YQh[XNiZHXjdoVie2ViaX6gR29ZNTJiZYjwdoV{e2mxbjDheEAyOCC3TR?=	M2T2W\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUG3O\|IyLz5{M{WxO\|czOTxxYU6=
HCA-7	NX35doh1TnWwY4Tpc44h[XO\|YYm=	NF\abVM2KHWP	MX2yOEBpenN?		M2n1VWlvcGmkaYTpc44hd2ZiaInhcJVzd26jbj3pcoR2[2WmIFPEOFR3PiCrbjDoeY1idiCKQ1GtO{Bk\WyuczD0doFve2[nY4Tl[EB4cXSqIFjhd\|JkTE6DIHHzd4V{e2WmIHHzJIRwf26{ZXf1cIF1cW:wIH;mJFUuVE:[IIDyc5RmcW5iZYjwdoV{e2mxbjDheEA2KHWPIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4T0bY5oKGGwYXz5d4l{	MXW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
HCA-7	MYjGeY5kfGmxbjDhd5NigQ>?	M{jyZVUhfU1?	MWOyOEBpenN?		Mn73TY5pcWKrdHnvckBw\iCqeXHseZJwdmGwLXnu[JVk\WRiQ1S0OJY3KGmwIHj1cYFvKEiFQT23JINmdGy\|IITyZY5{\mWldHXkJJdqfGhiSHHzNoNFVkFiYYPz[ZN{\WRiYYOg[I94dnKnZ4XsZZRqd25ib3[gR29ZNTJicILveIVqdiCneIDy[ZN{cW:wIHH0JFUhfU1iYX\0[ZIhOjRiaILzJIJ6KFenc4Tldo4h[myxdITpcoch[W6jbInzbZM>	MnHXQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{OUW3PFcoRjJ2Mkm1O\|g4RC:jPh?=
HCA-7	Ml\OSpVv[3Srb36gZZN{[Xl?	Ml7GOUB2VQ>?	NYL0dYdUOjRiaILz		NEDYUmtKdmirYnn0bY9vKG:oIHj5ZYx2em:wYX6tbY5lfWOnZDDDSFQ1fjZiaX6gbJVu[W5iSFPBMVch[2WubIOgeJJidnOoZXP0[YQhf2m2aDDIZZMz[0SQQTDhd5Nme3OnZDDhd{Bld3ewcnXneYxifGmxbjDv[kBEV1hvMTDwdo91\WmwIHX4dJJme3Orb36gZZQhPSC3TTDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0eIlv\yCjbnHsfZNqew>?	MU[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDJ7NUe4O{c,OjR{OUW3PFc9N2F-
HeLa	MVHGeY5kfGmxbjDhd5NigQ>?	M2nI[lExOCC3TR?=	NHXXb\|EzPCCqcoO=		NILnZ29KdmirYnn0bY9vKG:oIH3QS2VUNTFiaX6gbJVu[W5iSHXMZUBk\WyuczD1d4lv\yCSR1iyJIF{KHO3YoP0doF1\SCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKEmOLUHi[ZRiN1SQRnHsdIhiNXO2aX31cIF1\WRiUFfFNkBxem:mdXP0bY9vKGG2IEGwNEB2VSCjZoTldkAzPCCqcoOgZpkhVENvTWOvUXMh[W6jbInzbZM>	NFy2SnI9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEG4N\|c{QSd-MkSxPFM4Ozl:L3G+
HeLa	MYHGeY5kfGmxbjDhd5NigQ>?	M4rQblAvOSC3TR?=	MYqyOEBpenN?		MmjQTY5pcWKrdHnvckBw\iCSR1WyJJNm[3KndHnvckBqdiCqdX3hckBJ\UyjIHPlcIx{KGG2IECuNUB2VSCjZoTldkAzPCCqcoOgZpkhTUmDIH3vco9kdG:wYXygZZN{[Xl?	NEDHS4c9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O0PVM{OSd-MkezOFk{OzF:L3G+
Saos-2	NXnvSlFzeUiWUzDhd5NigQ>?				NHv3dpZyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU3Hvd{0zKGOnbHzz	M1fVTlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RAW264.7	MlrWRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?	NV;OWndKOjBidV2=	NGrvSXEzKGi{cx?=		NIC3co5CdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUlHXNlY1NjdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNiaX7keYNm\CClb4itNkBmgHC{ZYPzbY9vKGG2IEKwJJVOKHC{ZXnuZ5Vj[XSnZDDmc5IhOiCqcoOg[o9tdG:5ZXSgZpkhVFCVIHPoZYxt\W6pZTDt[YF{fXKnZDDh[pRmeiB{NDDodpMh[nliV3XzeIVzdiCkbH;0JI1mfGixZB?=	NWT1R5hDRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkmxNFA4QTlpPkK5NVAxPzl7PD;hQi=>
RAW264.7	MmLoRY51cWmwZnzhcY1ifG:{eTDhd5NigQ>?	MnXXNlAhfU1?	NYXwW2RHOiCqcoO=		NFvxfXNCdnSraX7mcIFudWG2b4L5JIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViUlHXNlY1NjdiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBNWFNiaX7keYNm\CCrTl;TJIV5eHKnc4Ppc44h[XRiMkCgeW0heHKnaX7jeYJifGWmIH\vdkAzKGi{czDmc4xtd3enZDDifUBNWFNiY3jhcIxmdmenIH3lZZN2emWmIHHmeIVzKDJ2IHjyd{BjgSCZZYP0[ZJvKGKub4SgcYV1cG:m	NFr0bmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUGwNFc6QSd-MkmxNFA4QTl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Fibronectin / Vimentin / N-cadherin / E-cadherin ; PubMed: 28978083 Oncotarget (A) Celecoxib treatment reduces the mesenchymal phenotype in SUM149 cells. COX-2; PubMed: 29515134 Sci Rep L02 cells exposed to PA (200 μM) with different concentrations of celecoxib (Cel, 5-40 μM) for 24 h. Celecoxib decreased protein expression of COX-2 compared with control as indicated by western blot. pAKT / AKT / PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunoblots from N1-S1 cells treated with different dose celecoxib for 48 h.	28978083 29515134 24721996
Immunofluorescence	PPARγ / PTEN ; PubMed: 24721996 Oncotarget Immunofluorescence analysis in N1-S1 cells treated with 10 μM celecoxib for 48 h.	24721996
Growth inhibition assay	Cell viability; PubMed: 28521485 Oncol Lett Celecoxib caused the concentration-dependent inhibition of (A) GBC-SD and (B) NOZ cell growth.	28521485

In vivo

Celecoxib exhibits a potent, oral anti-inflammatory activity. Celecoxib reduces acute inflammation in the carrageenan edema assay and chronic inflammation in the adjuvant arthritis model with ED50 of 7.1 mg/kg and 0.37 mg/kg/day, respectively. In addition, Celecoxib also exhibits analgesic activity in the Hargreaves hyperalgesia model with ED50 of 34.5 mg/kg. Besides, Celecoxib produces no acute GI toxicity in rats at doses up to 200 mg/kg and no chronic GI toxicity in rats at doses up to 600 mg/kg/day over 10 days. ^[1] In a C3Hf/KamLaw female mouse model, Celecoxib increases median survival time of 105 days (range, 79-145 days) after 13.5 Gy local thoracic irradiation (LTI) alone to 142 days (range, 94-155 days). ^[3]

Protocol

Kinase Assay:^[1]	- Collapse COX enzyme assay in vitro: Expression of COX protein in insect cells is determined by assessing PG-synthetic capability in homogenates from cells incubated for 3 days with COX-1 or COX-2 baculovirus. Cells expressing COX-1 or COX-2 are homogenized and incubated with arachidonic acid (10 μM). COX activity is determined by monitoring PG production. No COX activity is detected in mock-infected Sf9 cells. Celecoxib are preincubated with crude 1% CHAPS homogenates (2-10 μg of protein) for 10 minutes before addition of arachidonic acid. PGE2 formed is detected by ELISA after 10 minute incubation.
Cell Research:^[2]	- Collapse Cell lines: HNE1 and CNE1-LMP1 Concentrations: 0-75 μM Incubation Time: 48 hours Method: The antiproliferative effect of Celecoxib on NPC cells is assessed using an MTT assay. Cells are seeded into 96-well plates and allowed to attach for 24 hours. The cells are then treated with increasing concentrations of Celecoxib (0 to 75 μM) dissolved in DMSO (final concentration ≤0.1%) and incubated for up to 48 hours. After the incubation, 20 μL of MTT dye (5 mg/mL) are added to each well and cells are incubated at 37 °C for 4 hours. After removing the supernatants, the crystals are dissolved in DMSO and the absorbance is measured at 490 nm. The half-maximal inhibitory concentration (IC50) values and the 95% confidence intervals are calculated using probit regression using SPSS 15.0 software. The experiment is performed in triplicate and repeated at least three times. (Only for Reference)
Animal Research:^[1]	- Collapse Animal Models: A 0.1 mL aliquot of a 1% solution of carrageenan in 0.9% sterile saline or 1 mg of Mycobacterium butyricum in 50 μL of mineral oil is administered to the right hind foot pad of male Sprague−Dawley rats. Dosages: ≤200 mg/kg Administration: Administered via p.o. (Only for Reference)

References

Solubility (25°C)

In vitro	DMSO	76 mg/mL (199.28 mM)
	Water	Insoluble
	Ethanol	'33 mg/mL
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Celecoxib (SC 58635) SDF

Molecular Weight	381.37
Formula	C₁₇H₁₄F₃N₃O₂S
CAS No.	169590-42-5
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT01344200	Not yet recruiting	Drug: Celecoxib\|Drug: Placebo	Pharmacokinetics of Celecoxib in Children	Children''s Hospital of Eastern Ontario	January 2022	Phase 2
NCT04526197	Completed	Drug: ALXN1840\|Drug: Celecoxib	Wilson Disease	Alexion Pharmaceuticals	July 8 2020	Phase 1
NCT04447261	Completed	Drug: BI 1356225\|Drug: Placebo	Obesity	Boehringer Ingelheim	June 30 2020	Phase 1
NCT03896113	Recruiting	Drug: Celecoxib 200mg capsule	Endometrium Cancer	Cliniques universitaires Saint-Luc- Université Catholique de Louvain	November 13 2019	Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
I am doing an animal experiment with mice and planning to administrate S1261 via oral gavage. what are your recommendations for diluting the compound?
Answer:
For oral administration, Celecoxib can be dissolved in vehicle one: "0.5% methyl cellulose and 0.025% Tween-20", or the vehicle 2 "2% DMSO/30% PEG 300/5% Tween 80/ ddH2O".

COX Signaling Pathway Map

COX Inhibitors with Unique Features

Pan COX inhibitor

Naproxen : Pan-COX inhibitor, COX-1, IC50=8.7 μM; COX-2, IC50=5.2 μM.
Most Potent COX Inhibitor

Lornoxicam : COX-1, IC50=5 nM; COX-2, IC50=8 nM.
FDA-approved COX Inhibitor

Ibuprofen : Approved by FDA for relieving pain, alleviating fever,and reducing inflammation.
Classic COX Inhibitor

Ketorolac : Non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Related COX Products

Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
Nirogacestat (PF-03084014) ^New

Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2.
Indomethacin (NSC-77541)

Indomethacin (NSC-77541, Indometacin) is a nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively, used to reduce fever, pain, stiffness, and swelling.
Lornoxicam

Lornoxicam (Chlortenoxicam) is a non-steroidal COX-1/COX-2 inhibitor, used as an anti-inflammatory drug to treat pain, osteoarthritis, and rheumatoid arthritis.
Aspirin (NSC 27223)

Aspirin (NSC 27223, Acetylsalicylic acid, ASA) is a salicylate, and irreversible COX1 and COX2 inhibitor, used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin induces autophagy and stimulates mitophagy.
Rofecoxib

Rofecoxib (MK-0966) is a COX-2 inhibitor with IC50 of 18 nM.
Ketorolac

Ketorolac is a non-selective COX inhibitor of COX-1 and COX-2 with IC50 of 1.23 μM and 3.50 μM, respectively.

Features:A COX-1 preferential inhibitor among currently marked nonsteroidal anti-inflammatory drugs (NSAIDs).
Bufexamac

Bufexamac is a COX inhibitor for IFN-α release with EC50 of 8.9 μM.

Features:A specific inhibitor of class IIB histone deacetylases.
Ibuprofen (NSC 256857)

Ibuprofen (NSC 256857, Dolgesic) is an anti-inflammatory inhibitor targeting COX-1 and COX-2 with IC50 of 13 μM and 370 μM, respectively.

Features:Considered a core medicine in the WHO's "WHO Model List of Essential Medicines" (a list of the minimum medical requirements for a basic healthcare system).

Choose Your Country or Region

By Signaling Pathways

By product type

Celecoxib (SC 58635)